<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>Heart Failure Reviews via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Heart Failure Reviews' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Heart+Failure+Reviews&t=Heart+Failure+Reviews&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 09:32:41 +0100</lastBuildDate>
        <item>
            <title>Prevention of heart failure in the elderly: when, where and how to begin?</title>
            <link>http://www.medworm.com/index.php?rid=5638315&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa62403n518815653%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Significant growth in the elderly population (age&amp;nbsp;≥&amp;nbsp;65&amp;nbsp;years) with heart failure (HF) has taken place in developed countries
 and is occurring in most developing countries. Projections from population studies in the United States, Europe and other
 developed countries suggest that this trend will very likely continue and tax healthcare systems worldwide. Prevention of
 HF in the elderly should be a healthcare priority. Preventive strategies are urgently needed to combat the rising burden of
 HF and related complications in elderly men and women of tomorrow. The strategies should address the aging continuum and the
 cumulative impact of lifelong exposure to cardiovascular (CV) risk factors and consider the associated pathobiology and pathophysiology
 of ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638315</comments>
            <pubDate>Tue, 24 Jan 2012 07:20:23 +0100</pubDate>
            <guid isPermaLink="false">5638315</guid>        </item>
        <item>
            <title>The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: implications for heart failure in the elderly</title>
            <link>http://www.medworm.com/index.php?rid=5619896&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb8668211483lr985%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Dilated cardiomyopathy (DCM) is a common debilitating condition with limited therapeutic options besides heart transplantation
 or palliation. It is characterized by maladaptive remodeling of cardiomyocytes, extracellular collagen matrix (ECCM) and left
 ventricular (LV) geometry which contributes to further dysfunction. LV assist devices (LVADs) can reverse adverse remodeling
 in end-stage DCM. However, there is a disconnect between the benefits of prolonged unloading with LVAD at molecular and cellular
 levels and the low rate of bridge to recovery (BTR). Potential explanations for this paradox include insufficient reverse
 ECCM remodeling and/or excessive reverse cardiomyocyte remodeling with atrophy. LVAD therapy is associated with decreased
 collagen turnover and c...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5619896</comments>
            <pubDate>Thu, 19 Jan 2012 06:54:52 +0100</pubDate>
            <guid isPermaLink="false">5619896</guid>        </item>
        <item>
            <title>The continuing saga of aging and heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5619895&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F338240m2121n077n%2F</link>
            <description>Content Type Journal ArticlePages 1-2DOI 10.1007/s10741-012-9301-7Authors
		Bodh I. Jugdutt, Department of Medicine, Division of Cardiology, University of Alberta and Hospitals, 2C2 Walter MacKenzie Health Sciences Centre, Edmonton, AB T6G 2R7, Canada
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5619895</comments>
            <pubDate>Thu, 19 Jan 2012 06:54:52 +0100</pubDate>
            <guid isPermaLink="false">5619895</guid>        </item>
        <item>
            <title>Surgical approaches to left ventricular reconstruction: a matter of perspective</title>
            <link>http://www.medworm.com/index.php?rid=5619897&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa458714g0w415210%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Surgical reconstruction of physiological shape and size of a postischemically remodeled left ventricle has been advocated
 to improve ventricular function and improve patient long-term outcome. What initially started as linear aneurysm resection
 surgery developed over the years into the endoventricular repair techniques (surgical ventricular reconstruction, SVR) that
 have also been applied in patients with postischemically dilated ventricles and mainly anterior akinesia. SVR improved function
 as measured by the ejection fraction. Whether it affects survival was finally tested in the largest surgical trial ever conducted,
 the STICH trial (Surgical Treatment for IsChemic Heart failure). The trial, however, presented rather sobering information
 with its Hypothesis 2 o...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5619897</comments>
            <pubDate>Thu, 19 Jan 2012 06:54:51 +0100</pubDate>
            <guid isPermaLink="false">5619897</guid>        </item>
        <item>
            <title>Mechanical circulatory support for elderly heart failure patients</title>
            <link>http://www.medworm.com/index.php?rid=5597172&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr26161232035l8j3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;End-stage systolic heart failure is an increasingly common problem in elderly patients and is associated with high cost, poor
 quality of life, and poor outcomes. Mechanical circulatory support is a promising therapy as both a bridge to transplantation
 and destination therapy. Elderly patients are frequently ineligible for heart transplantation because of their age and comorbidities,
 and the application of mechanical circulatory support for destination therapy in this population is not well defined. A review
 of the literature was undertaken to better characterize our experience to date with mechanical circulatory support in older
 heart failure populations. Mechanical circulatory support is being employed increasingly for destination therapy indications
 in older pat...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597172</comments>
            <pubDate>Wed, 11 Jan 2012 17:57:58 +0100</pubDate>
            <guid isPermaLink="false">5597172</guid>        </item>
        <item>
            <title>Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=5572067&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv84887v88l04h4t2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure syndromes are often associated with multi-organ dysfunction, and concomitant liver, renal, and neurologic involvement
 is very common. Neuro-hormonal antagonism plays a key role in the management of this syndrome, and angiotensin-converting
 enzyme inhibitors and angiotensin receptor blockers are one of the cornerstones of therapy. Cardiorenal physiology is becoming
 more recognized in these patients with advanced heart failure, and the role of neuro-hormonal blockade in this setting is
 vaguely defined in the literature. Often, angiotensin-converting enzyme inhibitors are decreased or even withheld in these
 circumstances. The purpose of this article is to review the role and pathophysiology of ace inhibition and angiotensin receptor
 blockade in patients...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5572067</comments>
            <pubDate>Mon, 02 Jan 2012 16:48:16 +0100</pubDate>
            <guid isPermaLink="false">5572067</guid>        </item>
        <item>
            <title>Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy</title>
            <link>http://www.medworm.com/index.php?rid=5504586&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqq887066065n7v28%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Clinical trials for acute heart failure syndromes (AHFS) have traditionally enrolled patients well after emergency department
 (ED) presentation. We hypothesized a large proportion of patients would undergo changes in clinical profiles during the first
 24&amp;nbsp;h of hospitalization, and these changes would be associated with adverse events. We evaluated a prospective cohort of patients
 with clinical data available at ED presentation and 12–24&amp;nbsp;h after ED treatment for AHFS. Patients were categorized into distinct
 clinical profiles at these time points based on (1) systolic blood pressure: a—hypertensive (&amp;gt;160&amp;nbsp;mmHg); b—normotensive (100–159&amp;nbsp;mmHg);
 or c—hypotensive (&amp;lt;100&amp;nbsp;mmHg); (2) moderate-to-severe renal dysfunction (GFR&amp;nbsp;≤&amp;nb...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504586</comments>
            <pubDate>Mon, 12 Dec 2011 17:06:40 +0100</pubDate>
            <guid isPermaLink="false">5504586</guid>        </item>
        <item>
            <title>Determinants of heart failure self-care: a systematic literature review</title>
            <link>http://www.medworm.com/index.php?rid=5476319&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk7141kr14n614802%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Self-care is an important aspect of heart failure (HF) management. Information on the determinants of self-care is necessary
 for the development of self-care promotion interventions. HF self-care includes self-care management, self-care maintenance,
 sodium, fluid and alcohol intake restriction, physical activity, smoking cessation, monitoring signs and symptoms and keeping
 follow-up appointments. To assess the evidence regarding presumed determinants of HF self-care and make recommendations for
 interventions to promote self-care behavior among HF patients, a systematic literature review was conducted. Based on inclusion
 and exclusion criteria and a quality assessment, twenty-six articles were included. A best evidence synthesis was used. Results
 showed that the le...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5476319</comments>
            <pubDate>Thu, 01 Dec 2011 19:22:39 +0100</pubDate>
            <guid isPermaLink="false">5476319</guid>        </item>
        <item>
            <title>Age-related cardiovascular disease and the beneficial effects of calorie restriction</title>
            <link>http://www.medworm.com/index.php?rid=5431571&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd71612jl136116lu%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Aging is a well-recognized risk factor in the development of cardiovascular disease, which is the primary cause of death and
 disability in the elderly population. The normal process of aging is associated with progressive deterioration in structure
 and function of the heart and vasculature. These age-related changes likely act as both a catalyst and accelerator in the
 development of cardiovascular disease. Since the aging population is one of the fastest growing segments of the population,
 it is of vital importance that we have a thorough understanding of the physiological changes that occur with aging that contribute
 to the high incidence of cardiovascular disease in this population. This insight will allow for the development of more targeted
 therapies that can ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5431571</comments>
            <pubDate>Fri, 18 Nov 2011 06:59:13 +0100</pubDate>
            <guid isPermaLink="false">5431571</guid>        </item>
        <item>
            <title>The cardiorenal syndrome in heart failure: cardiac? renal? syndrome?</title>
            <link>http://www.medworm.com/index.php?rid=5421833&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd05011n981285150%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;There has been increasing interest on the so-called cardiorenal syndrome (CRS), defined as a complex pathophysiological disorder
 of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the
 other. In this review, we contend that there is lack of evidence warranting the adoption of a specific clinical construct
 such as the CRS within the heart failure (HF) syndrome by demonstrating that: (a) the approaches and tools regarding the definition
 of kidney involvement in HF are suboptimal; (b) development of renal failure in HF is often confounded by age, hypertension,
 and diabetes; (c) worsening of renal function (WRF) in HF may be largely independent of alterations in cardiac function; (d)
 the bidirectional a...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5421833</comments>
            <pubDate>Tue, 15 Nov 2011 17:00:44 +0100</pubDate>
            <guid isPermaLink="false">5421833</guid>        </item>
        <item>
            <title>The determinants of clinical outcome and clinical response to CRT are not the same</title>
            <link>http://www.medworm.com/index.php?rid=5407569&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcm92253w62561308%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The purpose of treatment is to alter outcomes favourably. From a clinical perspective, these outcomes may include symptoms,
 quality of life, disability, morbidity and mortality. However, a good outcome does not mean that the intervention was effective
 and a seemingly poor outcome could have been worse without intervention. Patients may have a good outcome either because their
 disease was due to run a benign course, or because they responded to the intended treatment or because they responded to some
 other ancillary treatment. Clearly, there is a link between response and outcome but it is loose and uncertain. The clinical
 substrate being treated is often a stronger determinant of outcome than the response to the intervention. The concepts of
 outcome and response c...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407569</comments>
            <pubDate>Fri, 11 Nov 2011 12:48:11 +0100</pubDate>
            <guid isPermaLink="false">5407569</guid>        </item>
        <item>
            <title>Erythropoietin: a future therapy for failing hearts?</title>
            <link>http://www.medworm.com/index.php?rid=5386026&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl8q231271379q336%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recently, it has been suggested that erythropoietin may be useful in the treatment of cardiovascular disease, particularly
 heart failure. This may be by improving microvascular blood supply and ventricular function through prevention of apoptosis
 and angiogenesis. Promising results were seen in animals but the few, limited clinical trials have shown modest benefits.
 Additionally, concerns exist regarding potential serious adverse effects of erythropoietin. Our current understanding of the
 non-haematopoietic mechanisms of erythropoietin is presented here, with a review of trials to date, and a discussion of the
 questions that remain over the use of this drug in heart failure.
 
 
	Content Type Journal ArticlePages 1-9DOI 10.1007/s10741-011-9288-5Authors
		Lindsey Ti...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5386026</comments>
            <pubDate>Fri, 04 Nov 2011 05:43:39 +0100</pubDate>
            <guid isPermaLink="false">5386026</guid>        </item>
        <item>
            <title>Atrial fibrillation and heart failure in the elderly</title>
            <link>http://www.medworm.com/index.php?rid=5386027&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F18mv0726580v4856%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Atrial fibrillation (AF) is a common clinical problem in elderly patients and especially in those with heart failure (HF).
 It is a major risk factor for serious cardiovascular events, such as stroke, HF and premature death. Both the prevalence and
 incidence of AF increase with age and its prevalence in the United States are estimated at more than 2.2 million, with nearly
 75% of patients aged &amp;gt;65&amp;nbsp;years. Aging-related atrial remodeling with fibrosis, dilation and mitochondrial DNA mutations predispose
 elderly patients to AF. Current management options for AF, including rate control and anticoagulation therapy, can be successfully
 applied to the elderly population. New antiarrhythmic and anticoagulation medications such as dronedarone and dabigatran,
 respecti...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5386027</comments>
            <pubDate>Thu, 03 Nov 2011 16:57:49 +0100</pubDate>
            <guid isPermaLink="false">5386027</guid>        </item>
        <item>
            <title>How to improve outcomes with cardiac resynchronisation therapy: importance of lead positioning</title>
            <link>http://www.medworm.com/index.php?rid=5335444&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr27774341p607268%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac resynchronisation therapy (CRT), by retiming the failing heart, improves symptoms, reduces hospitalisations and improves
 survival in patients with left ventricular dysfunction and QRS prolongation. However, not all patients “respond” to CRT. Successful
 CRT depends on appropriate patient selection, optimal lead positioning, device programming/optimisation and optimal medical
 therapy. This review article focuses on the importance of lead positioning in improving outcomes.
 
 
	Content Type Journal ArticlePages 1-9DOI 10.1007/s10741-011-9287-6Authors
		Peter J. Cowburn, Wessex Cardiac Unit, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD UKChristophe Leclercq, Départment de Cardiologie et Maladies Vasculaires, CHU, Pontchaillou, 2, rue Hen...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335444</comments>
            <pubDate>Wed, 19 Oct 2011 05:50:28 +0100</pubDate>
            <guid isPermaLink="false">5335444</guid>        </item>
        <item>
            <title>Systolic heart failure in the elderly: optimizing medical management</title>
            <link>http://www.medworm.com/index.php?rid=5335445&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3088k721676m4500%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aging population with hypertension and coronary artery disease is rapidly increasing worldwide and develops heart failure
 (HF). A wide range of pharmacotherapeutic drugs are recommended in the HF management guidelines. For the most part, these
 recommendations are based on the results of studies in the younger population, and most drugs were not adequately tested in
 the elderly. However, many changes that occur during the aging process affect the response to several of the recommended therapeutic
 drugs. Physicians will be increasingly involved in managing the expanding elderly population with HF. It is therefore imperative
 that they recognize ways to use current pharmacotherapeutic agents and the increasing need for novel agents for optimizing
 the management of...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335445</comments>
            <pubDate>Sun, 16 Oct 2011 15:37:42 +0100</pubDate>
            <guid isPermaLink="false">5335445</guid>        </item>
        <item>
            <title>Atherosclerotic disease of the abdominal aorta and its branches: prognostic implications in patients with heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5323827&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr9k5200321642788%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Aortic atherosclerosis reduces compliance in the systemic circulation and increases peripheral resistance, afterload and left
 ventricular wall stress. In patients with heart failure, these changes can impair left ventricular systolic function and energy
 efficiency, which could reduce exercise capacity. Though the interaction and the impact of aortic atherosclerosis on left
 ventricular function have been investigated, its prognostic implications in patients with heart failure are unclear. We used
 cardiac magnetic resonance imaging and gadolinium-enhanced abdominal aortography to investigate the prevalence and prognostic
 impact of atherosclerotic disease of the abdominal aorta and its side branches in 355 patients with heart failure. Sclerotic
 abdominal aortic disea...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5323827</comments>
            <pubDate>Fri, 14 Oct 2011 10:39:26 +0100</pubDate>
            <guid isPermaLink="false">5323827</guid>        </item>
        <item>
            <title>Intrinsic skeletal muscle alterations in chronic heart failure patients: a disease-specific myopathy or a result of deconditioning?</title>
            <link>http://www.medworm.com/index.php?rid=5323828&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq123r2401g134173%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic heart failure (CHF) patients frequently experience impaired exercise tolerance due to skeletal muscle fatigue. Studies
 suggest that this in part is due to intrinsic alterations in skeletal muscle of CHF patients, often interpreted as a disease-specific
 myopathy. Knowledge about the mechanisms underlying these skeletal muscle alterations is of importance for the pathophysiological
 understanding of CHF, therapeutic approach and rehabilitation strategies. We here critically review the evidence for skeletal
 muscle alterations in CHF, the underlying mechanisms of such alterations and how skeletal muscle responds to training in this
 patient group. Skeletal muscle characteristics in CHF patients are very similar to what is reported in response to chronic
 obstruct...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5323828</comments>
            <pubDate>Fri, 14 Oct 2011 05:50:39 +0100</pubDate>
            <guid isPermaLink="false">5323828</guid>        </item>
        <item>
            <title>The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5323829&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp9634496611055p6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mineralocorticoid receptor antagonists (MRAs) have been effective in reducing total mortality in patients with heart failure
 (HF) and a reduced left ventricular ejection fraction. Due to the finding that aldosterone levels decrease with age, one might
 question the effectiveness of MRAs in very old patients (≥80&amp;nbsp;years of age), those at the greatest risk for developing HF with
 a preserved left ventricular ejection fraction (PEF). However, while aldosterone levels decrease with age, there is also a
 decrease in the enzyme 11 beta HSD2 levels with age, thereby allowing cortisol to stimulate the mineralocorticoid receptor
 (MR), which in younger patients with higher levels of 11 beta HSD 2 levels is converted to cortisone which cannot activate
 the MR. There is als...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5323829</comments>
            <pubDate>Fri, 14 Oct 2011 05:50:38 +0100</pubDate>
            <guid isPermaLink="false">5323829</guid>        </item>
        <item>
            <title>Angiogenic therapy for cardiac repair based on protein delivery systems</title>
            <link>http://www.medworm.com/index.php?rid=5304257&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F805u23qut328h334%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiovascular diseases remain the first cause of morbidity and mortality in the developed countries and are a major problem
 not only in the western nations but also in developing countries. Current standard approaches for treating patients with ischemic
 heart disease include angioplasty or bypass surgery. However, a large number of patients cannot be treated using these procedures.
 Novel curative approaches under investigation include gene, cell, and protein therapy. This review focuses on potential growth
 factors for cardiac repair. The role of these growth factors in the angiogenic process and the therapeutic implications are
 reviewed. Issues including aspects of growth factor delivery are presented in relation to protein stability, dosage, routes,
 and safety m...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304257</comments>
            <pubDate>Fri, 07 Oct 2011 05:47:20 +0100</pubDate>
            <guid isPermaLink="false">5304257</guid>        </item>
        <item>
            <title>Anemia in chronic heart failure: Can we treat? What to treat?</title>
            <link>http://www.medworm.com/index.php?rid=5304258&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff316417764522t31%2F</link>
            <description>This article aims to review the aspects of anemia in chronic HF that
 are relevant for making treatment decisions, beginning with the definition of anemia and its incidence and prevalence of anemia
 in patients with chronic HF. Considering the etiology and prognostic impact of anemia in chronic HF, several treatment options
 will be considered. The latter are the application of erythropoiesis-stimulating agents (erythropoietin or darbepoetin alfa)
 or in the application of intravenous iron (e.g., iron carboxymaltose). According to the results seen in the FAIR-HF trial,
 iron supplementation should be particularly considered to improve symptoms and quality of life. Intravenous iron application
 may result in higher compliance and much faster treatment response than oral iron. The RED-HF stu...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304258</comments>
            <pubDate>Fri, 07 Oct 2011 05:47:19 +0100</pubDate>
            <guid isPermaLink="false">5304258</guid>        </item>
        <item>
            <title>Increasing knowledge and changing views in cardiac resynchronization therapy</title>
            <link>http://www.medworm.com/index.php?rid=5260421&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp210857up7668204%2F</link>
            <description>Content Type Journal ArticlePages 1-5DOI 10.1007/s10741-011-9281-zAuthors
		Laszlo Buga, Academic Cardiology, University of Hull, Castle Hill Hospital, MRTDS Building, Castle Road, Cottingham, Kingston-upon-Hull, HU16 5JQ UKJohn GF Cleland, Academic Cardiology, University of Hull, Castle Hill Hospital, MRTDS Building, Castle Road, Cottingham, Kingston-upon-Hull, HU16 5JQ UK
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5260421</comments>
            <pubDate>Tue, 20 Sep 2011 05:48:49 +0100</pubDate>
            <guid isPermaLink="false">5260421</guid>        </item>
        <item>
            <title>A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial</title>
            <link>http://www.medworm.com/index.php?rid=5260422&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnp102333g82n6716%2F</link>
            <description>The objectives of this study were to describe the baseline, in-hospital, and post-discharge clinical, laboratory, and neurohormonal
 profiles of patients hospitalized for worsening heart failure with reduced ejection fraction (EF) who die or are re-admitted
 for cardiovascular (CV) causes within 90 days of initial hospitalization. Retrospective analysis of 4,133 patients hospitalized
 for worsening heart failure with EF ≤40% in the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan
 (EVEREST) trial, which randomized patients to tolvaptan or placebo, both in addition to standard therapy. Clinical and laboratory
 parameters were obtained within 48&amp;nbsp;h of admission, during hospitalization, and post-discharge weeks 1, 4, 8, and every 8&amp;nbsp;weeks
 thereafter...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5260422</comments>
            <pubDate>Tue, 20 Sep 2011 05:46:43 +0100</pubDate>
            <guid isPermaLink="false">5260422</guid>        </item>
        <item>
            <title>Animal models of cardiorenal syndrome: a review</title>
            <link>http://www.medworm.com/index.php?rid=5225185&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F84q0624148742586%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The incidence of heart failure and renal failure is increasing and is associated with poor prognosis. Moreover, these conditions
 do often coexist and this coexistence results in worsened outcome. Various mechanisms have been proposed as an explanation
 of this interrelation, including changes in hemodynamics, endothelial dysfunction, inflammation, activation of renin-angiotensin-aldosterone
 system, and/or sympathetic nervous system. However, the exact mechanisms initializing and maintaining this interaction are
 still unknown. In many experimental studies on cardiac or renal dysfunction, the function of the other organ was either not
 addressed or the authors failed to show any decline in its function despite histological changes. There are few studies in
 which the d...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5225185</comments>
            <pubDate>Sat, 10 Sep 2011 05:46:22 +0100</pubDate>
            <guid isPermaLink="false">5225185</guid>        </item>
        <item>
            <title>Cardiac remodeling and subcellular defects in heart failure due to myocardial infarction and aging</title>
            <link>http://www.medworm.com/index.php?rid=5161401&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe4676450555548u2%2F</link>
            <description>This article is intended to discuss that cardiac dysfunction in hearts failing due to myocardial infarction and aging
 is associated with cardiac remodeling and defects in the subcellular organelles such as sarcolemma (SL), sarcoplasmic reticulum
 (SR), and myofibrils. Despite some differences in the pattern of heart failure due to myocardial infarction and aging with
 respect to their etiology and sequence of events, evidence has been presented to show that subcellular remodeling plays a
 critical role in the occurrence of intracellular Ca2+-overload and development of cardiac dysfunction in both types of failing heart. In particular, alterations in gene expression
 for SL and SR proteins induce Ca2+-handling abnormalities in cardiomyocytes, whereas those for myofibrillar proteins impair ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161401</comments>
            <pubDate>Thu, 18 Aug 2011 05:50:03 +0100</pubDate>
            <guid isPermaLink="false">5161401</guid>        </item>
        <item>
            <title>Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially</title>
            <link>http://www.medworm.com/index.php?rid=5109204&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv76163n088742j56%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure may lead to acute kidney injury and viceversa. Chronic kidney disease may affect the clinical outcome in terms
 of cardiovascular morbidity and mortality while chronic heart failure may cause CKD. All these disorders contribute to the
 composite definition of cardio-renal syndromes. Renal impairment in HF patients has been increasingly recognized as an independent
 risk factor for morbidity and mortality; however, the most important clinical trials in HF tend to exclude patients with significant
 renal dysfunction. The mechanisms whereby renal insufficiency worsens the outcome in HF are not known, and several pathways
 could contribute to the “vicious heart/kidney circle.” Traditionally, renal impairment has been attributed to the renal hypoperfusion
 ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5109204</comments>
            <pubDate>Sat, 06 Aug 2011 05:59:39 +0100</pubDate>
            <guid isPermaLink="false">5109204</guid>        </item>
        <item>
            <title>Heart failure with preserved ejection fraction in the elderly: scope of the problem</title>
            <link>http://www.medworm.com/index.php?rid=5109205&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0477jg7144385pu7%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure is an epidemic in the elderly and has become a leading cause for hospitalization and death. Heart failure with
 preserved ejection fraction (HFPEF) is more common than heart failure with reduced ejection fraction (HFREF) but disease identification
 remains challenging. Current criteria rely on symptoms of poor exercise tolerance, preserved ejection fraction and laboratory
 evidence for elevated filling pressures. Each of these clinical parameters is difficult to evaluate in the elderly and reduce
 the certainty of diagnosis. Aging is associated with changes in the peripheral vasculature, pulmonary function, oxygen transport
 and skeletal muscle function, all key determinants of exercise capacity. Furthermore, co-morbid conditions such as chronic
 obstructi...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5109205</comments>
            <pubDate>Fri, 05 Aug 2011 06:02:25 +0100</pubDate>
            <guid isPermaLink="false">5109205</guid>        </item>
        <item>
            <title>CRT or CRT-D devices? The case for ‘high energy’ devices</title>
            <link>http://www.medworm.com/index.php?rid=5109206&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9331g4h11g5v3371%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The decision to implant a CRT or CRT-D device is an important one that requires a careful look at the patient and discussion
 with the patient as to the benefits and risks associated with each approach. The good news is that CRT provided in any device
 is a robust therapy that improves many measures of heart failure outcome in very high-risk patients. We argue that in most
 circumstances, it is much easier to turn a tachycardia device off than not to have the benefit of prompt defibrillation should
 a tachycardia event occur. While cost is always a consideration, the responsibility of the physician is to individualize patient
 care and advocate for each patient, based upon the best available therapies.
 
 
	Content Type Journal ArticlePages 1-3DOI 10.1007/s10741-011-927...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5109206</comments>
            <pubDate>Thu, 04 Aug 2011 15:41:15 +0100</pubDate>
            <guid isPermaLink="false">5109206</guid>        </item>
        <item>
            <title>Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease</title>
            <link>http://www.medworm.com/index.php?rid=5103802&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8k22w87040341450%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Important changes occur in the cardiovascular system with advancing age, even in apparently healthy individuals. Thickening
 and stiffening of the large arteries develop due to collagen and calcium deposition and loss of elastic fibers in the medial
 layer. These arterial changes cause systolic blood pressure to rise with age, while diastolic blood pressure generally declines
 after the sixth decade. In the left ventricle, modest concentric wall thickening occurs due to cellular hypertrophy, but cavity
 size does not change. Although left ventricular systolic function is preserved across the age span, early diastolic filling
 rate declines 30–50% between the third and ninth decades. Conversely, an age-associated increase in late diastolic filling
 due to atrial contra...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5103802</comments>
            <pubDate>Tue, 02 Aug 2011 05:52:29 +0100</pubDate>
            <guid isPermaLink="false">5103802</guid>        </item>
        <item>
            <title>Left ventricular dyssynchrony: a dynamic condition</title>
            <link>http://www.medworm.com/index.php?rid=5088080&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0427251kpm041015%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Left ventricular dyssynchrony (LVD) is common in heart failure patients with LV systolic dysfunction. Contrary to what it
 could be expected, LVD is not a stable phenomenon. Various conditions (inducible ischemia, exercise, drug administration)
 may significantly alter the presence and the magnitude of LVD, which could per se modulate response to treatment for heart
 failure. LVD can be evaluated using validated Doppler-echocardiographic techniques as tissue Doppler imaging. Exercise and
 dobutamine stress echocardiography can be used tests to unmask LVD. Changes in LV synchronicity during stress test occur independently
 of inducible ischemia and irrespective of QRS width. The degree of LVD varies substantially from patient to patient. The dynamic
 increase in LVD repr...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5088080</comments>
            <pubDate>Fri, 29 Jul 2011 05:54:56 +0100</pubDate>
            <guid isPermaLink="false">5088080</guid>        </item>
        <item>
            <title>Cardiac resynchronization therapy is certainly cardiac therapy, but how much resynchronization and how much atrioventricular delay optimization?</title>
            <link>http://www.medworm.com/index.php?rid=5088081&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr5736l21p6563807%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac resynchronization therapy has become a standard therapy for patients who are refractory to optimal medical therapy
 and fulfill the criteria of QRS &amp;gt;120&amp;nbsp;ms, ejection fraction &amp;lt;35% and NYHA class II, III or IV. Unless there is some other heretofore
 unrecognized effect of pacing, the benefits of atrio-biventricular pacing on hard outcomes observed in randomized trials can
 only be attributed to the physiological changes it induces such as increases in cardiac output and/or reduction in myocardial
 oxygen consumption leading to an improvement in cardiac function efficiency. The term “Cardiac Resynchronization Therapy”
 for biventricular pacing presupposes that restoration of synchrony (simultaneity of timing) between left and right ventricles
 and/o...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5088081</comments>
            <pubDate>Wed, 27 Jul 2011 18:47:12 +0100</pubDate>
            <guid isPermaLink="false">5088081</guid>        </item>
        <item>
            <title>Right side of heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5088082&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F15nw35333146248x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The function of the right ventricle (RV) in heart failure (HF) has been mostly ignored until recently. A 2006 report of the
 National Heart, Lung, and Blood Institute identified a gap between RV research efforts and its clinical importance compared
 with that of the left ventricle. This recent shift in paradigm is fueled by the prognostic value ascribed to RV failure in
 HF and morbidity/mortality after myocardial infarction and surgery. In this review, we examine the significance of RV failure
 in the HF setting, its clinical presentation and pathophysiology, and ways to evaluate RV function using echocardiographic
 measurements. Furthermore, we discuss the medical management of RV failure including traditional therapies like beta-blockers
 and newer options like nitri...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5088082</comments>
            <pubDate>Wed, 27 Jul 2011 18:47:11 +0100</pubDate>
            <guid isPermaLink="false">5088082</guid>        </item>
        <item>
            <title>A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy</title>
            <link>http://www.medworm.com/index.php?rid=5063513&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F465672m0g3848253%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Spectacular developments have taken place, in the last 10&amp;nbsp;years, in the device-based management of heart failure (HF). Patients
 presenting with chronic HF may benefit from a device implanted with a view to: (1) resynchronise the pump function of a discoordinated
 failing heart or (2) prevent sudden arrhythmic death by automatic cardioversion or defibrillation. This “point-of-view” article
 reviews the large amount of information gathered in the past 10&amp;nbsp;years on the use of cardiac resynchronisation therapy (CRT),
 with or without cardioverter defibrillator (ICD), and puts in perspective the advisability of using one, the other or both
 treatments in distinct patient subsets. There is currently no strong scientific evidence supporting the systematic implant...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063513</comments>
            <pubDate>Sat, 23 Jul 2011 15:49:56 +0100</pubDate>
            <guid isPermaLink="false">5063513</guid>        </item>
        <item>
            <title>Ventricular resynchronization is the principle mechanism of benefit with cardiac resynchronization therapy</title>
            <link>http://www.medworm.com/index.php?rid=5063514&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0702q17wq134612l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although there is little debate over the fact that cardiac resynchronization therapy (CRT) can benefit the majority of patients
 selected with routine indications, the precise mechanism for improvement may be considered controversial. Among patients selected
 with New York Heart Association functional class III or IV symptoms, left ventricular ejection fraction ≤35% and electrocardiographic
 QRS widening of at least 120–130&amp;nbsp;ms, approximately 60–80% of patients improved depending on the definition of response used.
 Although a reasonable assumption is that electrocardiographic QRS widening is a surrogate for delays in regional ventricular
 mechanical activation, a large volume of data has demonstrated that there is a subset of patients with widened QRS complex...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063514</comments>
            <pubDate>Fri, 22 Jul 2011 17:02:06 +0100</pubDate>
            <guid isPermaLink="false">5063514</guid>        </item>
        <item>
            <title>Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment</title>
            <link>http://www.medworm.com/index.php?rid=5030269&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnx85630041334711%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Renal dysfunction is often present and/or worsens in patients with heart failure and this is associated with increased costs
 of care, complications and mortality. The cardiorenal syndrome can be defined as the presence or development of renal dysfunction
 in patients with heart failure. Its mechanisms are likely related to low cardiac output, increased venous congestion and renal
 venous pressure, neurohormonal and inflammatory activation and local changes, such as adenosine release. Many drugs, including
 loop diuretics, may contribute to worsening renal function through the activation of some of these mechanisms. Renal damage
 is conventionally defined by the increase in creatinine and blood urea nitrogen blood levels. However, these changes may be
 not related with ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5030269</comments>
            <pubDate>Tue, 12 Jul 2011 05:55:41 +0100</pubDate>
            <guid isPermaLink="false">5030269</guid>        </item>
        <item>
            <title>Role of various proteases in cardiac remodeling and progression of heart failure</title>
            <link>http://www.medworm.com/index.php?rid=5020368&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn4818p6082230845%2F</link>
            <description>This article discusses
 and compares how the activities of various proteases are involved in different cardiac abnormalities with respect to alterations
 in apoptotic pathways, cardiac remodeling, and cardiac dysfunction. An imbalance appears to occur between the activities of
 some proteases and their endogenous inhibitors in various types of hypertrophied and failing hearts, and this is likely to
 further accentuate subcellular remodeling and cardiac dysfunction. The importance of inhibiting the activities of both extracellular
 and intracellular proteases specific to distinct etiologies, in attenuating cardiac remodeling and apoptosis as well as biochemical
 changes of subcellular organelles, in heart failure has been emphasized. It is suggested that combination therapy to inhibit
 diff...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5020368</comments>
            <pubDate>Fri, 08 Jul 2011 06:33:22 +0100</pubDate>
            <guid isPermaLink="false">5020368</guid>        </item>
        <item>
            <title>Tissue inhibitor of metalloproteinases (TIMPs) in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4993636&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fyp2837vx36138148%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Remodeling of the myocardium and the extracellular matrix (ECM) occurs in heart failure irrespective of its initial cause.
 The ECM serves as a scaffold to provide structural support as well as housing a number of cytokines and growth factors. Hence,
 disruption of the ECM will result in structural instability as well as activation of a number of signaling pathways that could
 lead to fibrosis, hypertrophy, and apoptosis. The ECM is a dynamic entity that undergoes constant turnover, and the integrity
 of its network structure is maintained by a balance in the function of matrix metalloproteinases (MMPs) and their inhibitors,
 the tissue inhibitor of metalloproteinases (TIMPs). In heart disease, levels of MMPs and TIMPs are altered resulting in an
 imbalance between thes...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4993636</comments>
            <pubDate>Wed, 29 Jun 2011 15:52:04 +0100</pubDate>
            <guid isPermaLink="false">4993636</guid>        </item>
        <item>
            <title>New roles for renin and prorenin in heart failure and cardiorenal crosstalk</title>
            <link>http://www.medworm.com/index.php?rid=4970155&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F34276lt2571846ku%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The renin-angiotensin-aldosterone-system (RAAS) plays a central role in the pathophysiology of heart failure and cardiorenal
 interaction. Drugs interfering in the RAAS form the pillars in treatment of heart failure and cardiorenal syndrome. Although
 RAAS inhibitors improve prognosis, heart failure–associated morbidity and mortality remain high, especially in the presence
 of kidney disease. The effect of RAAS blockade may be limited due to the loss of an inhibitory feedback of angiotensin II
 on renin production. The subsequent increase in prorenin and renin may activate several alternative pathways. These include
 the recently discovered (pro-) renin receptor, angiotensin II escape via chymase and cathepsin, and the formation of various
 angiotensin subforms upstre...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970155</comments>
            <pubDate>Wed, 22 Jun 2011 06:07:32 +0100</pubDate>
            <guid isPermaLink="false">4970155</guid>        </item>
        <item>
            <title>Can we prevent or treat renal dysfunction in chronic heart failure?</title>
            <link>http://www.medworm.com/index.php?rid=4970154&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb734368892745tr5%2F</link>
            <description>In conclusion, prevention of renal dysfunction is possible
 in CHF, but treatment is still under investigation. New studies are necessary to establish whether a specific algorithm may
 be used to prevent renal dysfunction in CHF patients.
 
 
	Content Type Journal ArticlePages 1-8DOI 10.1007/s10741-011-9264-0Authors
		Daniela Dobre, INSERM, Center of Clinical Investigation - 9501, University Hospital Nancy, Lorrain Institute of Heart and Vessels Louis Mathieu, 4, rue du Morvan, 54500 Vandoeuvre-les-Nancy, FrancePatrick Rossignol, INSERM, Center of Clinical Investigation - 9501, University Hospital Nancy, Lorrain Institute of Heart and Vessels Louis Mathieu, 4, rue du Morvan, 54500 Vandoeuvre-les-Nancy, FranceMarco Metra, Institute of Cardiology, Department of Experimental and Applied Medic...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970154</comments>
            <pubDate>Wed, 22 Jun 2011 06:07:32 +0100</pubDate>
            <guid isPermaLink="false">4970154</guid>        </item>
        <item>
            <title>Resveratrol in cardiovascular disease: what is known from current research?</title>
            <link>http://www.medworm.com/index.php?rid=4970157&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl72w7577470k5183%2F</link>
            <description>This article will mainly review recently published basic researches about the protective cardiovascular
 effects of resveratrol because these results may lead to the development of new clinical therapeutics in patients.
 
 
	Content Type Journal ArticlePages 1-12DOI 10.1007/s10741-011-9260-4Authors
		Hong Wang, Centre for Coronary Heart Disease, Department of Cardiology, Fuwai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 BeiLiShi Rd, 100037 Xicheng District, Beijing, People’s Republic of ChinaYue-Jin Yang, Centre for Coronary Heart Disease, Department of Cardiology, Fuwai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 BeiLiShi Rd, 100037 Xicheng District, ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970157</comments>
            <pubDate>Tue, 21 Jun 2011 18:01:17 +0100</pubDate>
            <guid isPermaLink="false">4970157</guid>        </item>
        <item>
            <title>Pharmacotherapy of heart failure in the elderly: adverse events</title>
            <link>http://www.medworm.com/index.php?rid=4970156&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F51077741l1426271%2F</link>
            <description>This article
 reviews common adverse drug effects and drug interactions associated with HF therapy in older patients and discusses strategies
 for reducing the risk of adverse drug events. In order to minimize these risks, it is essential that clinicians avoid prescribing
 unnecessary medications, adjust medication dosages to optimally balance benefits and side effects, and remain ever vigilant
 to the potential for medications to cause or contribute to clinically important adverse events and impaired quality of life.
 In treating older HF patients, the oft-cited dictum “start low, go slow” clearly applies. Despite the inherent challenges,
 with careful management and close follow-up, most older HF patients can be successfully treated through the judicious use
 of guideline-recommended...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970156</comments>
            <pubDate>Tue, 21 Jun 2011 18:01:17 +0100</pubDate>
            <guid isPermaLink="false">4970156</guid>        </item>
        <item>
            <title>Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome</title>
            <link>http://www.medworm.com/index.php?rid=4970158&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F470r47478052xgg5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although inflammation is a physiologic response designed to protect us from infection, when unchecked and ongoing it may cause
 substantial harm. Both chronic heart failure (CHF) and chronic kidney disease (CKD) are known to cause elaboration of several
 pro-inflammatory mediators that can be detected at high concentrations in the tissues and blood stream. The biologic sources
 driving this chronic inflammatory state in CHF and CKD are not fully established. Traditional sources of inflammation include
 the heart and the kidneys which produce a wide range of pro-inflammatory cytokines in response to neurohormones and sympathetic
 activation. However, growing evidence suggests that non-traditional biomechanical mechanisms such as venous and tissue congestion
 due to volum...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970158</comments>
            <pubDate>Tue, 21 Jun 2011 18:01:16 +0100</pubDate>
            <guid isPermaLink="false">4970158</guid>        </item>
        <item>
            <title>The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4913451&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx5j3449485575507%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure is a progressive illness that carries significant morbidity and mortality. This highly prevalent illness leads
 to frequent, costly hospitalizations with approximately 50% of patients being readmitted within 6&amp;nbsp;months of initial hospitalization.
 While rehospitalization has been extensively studied in the past, little progress has been made in terms of reducing readmission
 rates of heart failure patients in the last decade despite increasing costs with impending resource limitations. We discuss
 disease-centered, physician-centered, and patient-centered factors that lead to rehospitalization as well as community/resource
 availability factors that contribute to rehospitalization of patients suffering from chronic heart failure. In addition, predictors...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4913451</comments>
            <pubDate>Sun, 05 Jun 2011 05:45:14 +0100</pubDate>
            <guid isPermaLink="false">4913451</guid>        </item>
        <item>
            <title>Role of ACE2 in diastolic and systolic heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4903981&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcw53rm7w13211313%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A novel angiotensin-converting enzyme (ACE) homolog, named ACE2, is a monocarboxypeptidase which metabolizes several peptides.
 ACE2 degrades Angiotensin (Ang) II, a peptide with vasoconstrictive/proliferative effects, to generate Ang-(1-7), which acting
 through its receptor Mas exerts vasodilatory/anti-proliferative actions. In addition, as ACE2 is a multifunctional enzyme
 and its actions on other vasoactive peptides can also contribute to its vasoactive effects including the apelin-13 and apelin-17
 peptides. The discovery of ACE2 corroborates the establishment of two counter-regulatory arms within the renin-angiotensin
 system. The first one is formed by the classical pathway involving the ACE-Ang II-AT1 receptor axis and the second arm is constituted by the ACE2-A...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4903981</comments>
            <pubDate>Fri, 03 Jun 2011 06:00:45 +0100</pubDate>
            <guid isPermaLink="false">4903981</guid>        </item>
        <item>
            <title>Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management</title>
            <link>http://www.medworm.com/index.php?rid=4903982&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb8j4474281gnt024%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure (HF) in the elderly is a major public health problem, and its prevalence is rising. Outcomes of HF in the elderly
 have not changed in the past 2 decades despite the introduction of novel HF therapies. This may be due to the combined impact
 of multiple comorbidities and frailty. The majority of elderly patients with HF are frail with multiple comorbidities. These
 comorbidities, along with frailty, contribute to the poor outcome of HF in the elderly and pose independent management challenges.
 More research is needed to better understand the interaction between frailty and multiple comorbidities and the mechanisms
 by which they impact HF and its management; develop prognostic tools that incorporate frailty and multiple comorbidities and
 provide more acc...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4903982</comments>
            <pubDate>Tue, 31 May 2011 05:56:30 +0100</pubDate>
            <guid isPermaLink="false">4903982</guid>        </item>
        <item>
            <title>Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment</title>
            <link>http://www.medworm.com/index.php?rid=4903983&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu143460x7362j858%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Diabetes mellitus is an important and prevalent risk factor for congestive heart failure. Diabetic cardiomyopathy has been
 defined as ventricular dysfunction that occurs in diabetic patients independent of a recognized cause such as coronary artery
 disease or hypertension. The disease course consists of a hidden subclinical period, during which cellular structural insults
 and abnormalities lead initially to diastolic dysfunction, later to systolic dysfunction, and eventually to heart failure.
 Left ventricular hypertrophy, metabolic abnormalities, extracellular matrix changes, small vessel disease, cardiac autonomic
 neuropathy, insulin resistance, oxidative stress, and apoptosis are the most important contributors to diabetic cardiomyopathy
 onset and progression. H...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4903983</comments>
            <pubDate>Fri, 27 May 2011 18:14:57 +0100</pubDate>
            <guid isPermaLink="false">4903983</guid>        </item>
        <item>
            <title>Current and novel renal biomarkers in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4903984&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb4327650m4q43525%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Renal function is the most important predictor of clinical outcome in heart failure (HF). It is therefore essential to have
 accurate and reliable measurement of renal function and early specific markers of renal impairment in patients with HF. Several
 renal functional entities exist, including glomerular filtration (GFR), glomerular permeability, tubulointerstitial damage,
 and endocrine function. Different markers have been studied that can be used to determine changes and the effect of treatment
 in these entities. In the present review, we summarize current and novel markers that give an assessment of renal function
 and prognosis in the setting of acute and chronic HF.
 
 
	Content Type Journal ArticlePages 1-10DOI 10.1007/s10741-011-9254-2Authors
		Kevin Damman, ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4903984</comments>
            <pubDate>Sat, 21 May 2011 23:05:52 +0100</pubDate>
            <guid isPermaLink="false">4903984</guid>        </item>
        <item>
            <title>Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels</title>
            <link>http://www.medworm.com/index.php?rid=4903985&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj3076123185383px%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The study tests the hypothesis that in patients admitted with acutely decompensated heart failure (ADHF), achievement of adequate
 body hydration status with intensive medical therapy, modulated by combined bioelectrical vectorial impedance analysis (BIVA)
 and B-type natriuretic peptide (BNP) measurement, may contribute to optimize the timing of patient’s discharge and to improve
 clinical outcomes. Three hundred patients admitted for ADHF underwent serial BIVA and BNP measurement. Therapy was titrated
 to reach a BNP value of &amp;lt;250&amp;nbsp;pg/ml, whenever possible. Patients were categorized as early responders (rapid BNP fall below
 250&amp;nbsp;pg/ml); late responders (slow BNP fall below 250&amp;nbsp;pg/ml, after aggressive therapy); and non-responders (BNP persistently
 &amp;...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4903985</comments>
            <pubDate>Sat, 21 May 2011 23:05:51 +0100</pubDate>
            <guid isPermaLink="false">4903985</guid>        </item>
        <item>
            <title>Pathophysiology and pathogenesis of post-resuscitation myocardial stunning</title>
            <link>http://www.medworm.com/index.php?rid=4842754&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F40414545155j3q27%2F</link>
            <description>This article
 covers a huge gap in the existing literature regarding the pathophysiology of post-resuscitation period and provides a better
 understanding of the pathophysiology and pathogenesis of post-resuscitation myocardial stunning.
 
 
	Content Type Journal ArticlePages 1-12DOI 10.1007/s10741-011-9255-1Authors
		Athanasios Chalkias, Department of Anatomy, Medical School, University of Athens, 75 Mikras Asias street, 11527 Athens, GreeceTheodoros Xanthos, Department of Anatomy, Medical School, University of Athens, 75 Mikras Asias street, 11527 Athens, Greece
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4842754</comments>
            <pubDate>Mon, 16 May 2011 15:47:08 +0100</pubDate>
            <guid isPermaLink="false">4842754</guid>        </item>
        <item>
            <title>What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies</title>
            <link>http://www.medworm.com/index.php?rid=4831078&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw116n8185h23x841%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Physical activity is recommended for people with stable heart failure (HF), because it is known to improve quality of life
 and health outcomes. However, adherence to this recommendation has been poor in many studies. A systematic review was conducted
 to examine the effectiveness of strategies used to promote exercise adherence in those with HF. The following databases were
 searched for relevant literature published between January 1980 and December 2010: British Nursing Index; CINAHL; Cochrane
 Library; Embase; Medline and PsycINFO. Papers with a control group focused on adults with HF that measured exercise or physical
 activity adherence were included. Nine randomised controlled trials were identified, involving a total of 3,231 patients (range
 16–2,331). Six of...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4831078</comments>
            <pubDate>Thu, 12 May 2011 16:45:30 +0100</pubDate>
            <guid isPermaLink="false">4831078</guid>        </item>
        <item>
            <title>Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis</title>
            <link>http://www.medworm.com/index.php?rid=4821799&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj73018884181vj13%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In the United States and Europe, approximately 90% of heart failure hospitalizations are due to symptoms and signs of sodium
 and fluid excess. Congestion is associated with heart failure progression. Venous congestion, rather than a reduced cardiac
 output, may be the primary hemodynamic factor driving worsening renal function in patients with acutely decompensated heart
 failure. According to data from large national registries, approximately 40% of hospitalized heart failure patients are discharged
 with unresolved congestion, which may contribute to unacceptably high re-hospitalization rates. Diuretics reduce the symptoms
 and signs of fluid overload, but their effectiveness can be reduced by excess salt intake, underlying chronic kidney disease,
 renal adaptation t...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821799</comments>
            <pubDate>Wed, 11 May 2011 06:24:23 +0100</pubDate>
            <guid isPermaLink="false">4821799</guid>        </item>
        <item>
            <title>Can we prevent or treat renal dysfunction in acute heart failure?</title>
            <link>http://www.medworm.com/index.php?rid=4821800&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F750t32p15u5t18tn%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Most patients with heart failure (HF) already have or develop renal dysfunction; this might contribute to their poor outcome.
 Current treatment for HF can also contribute to worsen renal function. High furosemide doses are traditionally associated
 with worsening renal function (WRF), but patients with fluid overload may benefit of aggressive fluid removal. Unfortunately,
 promising therapies like vasopressin antagonists and adenosine antagonists have not been demonstrated to improve outcomes.
 Likewise, correction of low renal blood flow through dopamine, inotropic agents, or vasodilators does not seem to be associated
 with a clear benefit. However, transient WRF associated with acute HF treatment may not necessarily portend a poor prognosis.
 In this review, we focu...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821800</comments>
            <pubDate>Tue, 10 May 2011 06:06:13 +0100</pubDate>
            <guid isPermaLink="false">4821800</guid>        </item>
        <item>
            <title>Erratum to: Epidemiology and outcome of the cardio-renal syndrome</title>
            <link>http://www.medworm.com/index.php?rid=4821801&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm3k865002k16040r%2F</link>
            <description>Content Type Journal ArticlePages 1-1DOI 10.1007/s10741-011-9251-5Authors
		Dinna N. Cruz, Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, ItalyMihai Gheorghiade, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAlberto Palazzuoli, Department of Internal Medicine and Metabolic Disease, Cardiology Section, University of Siena, Siena, ItalyClaudio Ronco, Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, ItalySean M. Bagshaw, Division of Critical Care Medicine, University of Alberta Hospital, 3C1.12 Walter C. Mackenzie Centre, 8440-122 Street, Edmonton, AB T6G2B7, Canada
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Re...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4821801</comments>
            <pubDate>Tue, 10 May 2011 06:06:12 +0100</pubDate>
            <guid isPermaLink="false">4821801</guid>        </item>
        <item>
            <title>Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4805749&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft00g9753338302m8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart and kidney interactions are fascinating, in the sense that failure of the one organ strongly affects the function of
 the other. In this review paper, we analyze how principal driving forces for glomerular filtration and renal blood flow are
 changed in heart failure. Moreover, renal autoregulation and modulation of neurohumoral factors, which can both have repercussions
 on renal function, are analyzed. Two paradigms seem to apply. One is that the renin-angiotensin system (RAS), the sympathetic
 nervous system (SNS), and extracellular volume control are the three main determinants of renal function in heart failure.
 The other is that the classical paradigm to analyze renal dysfunction that is widely applied in nephrology also applies to
 the pathophysiology of h...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4805749</comments>
            <pubDate>Sat, 07 May 2011 15:43:24 +0100</pubDate>
            <guid isPermaLink="false">4805749</guid>        </item>
        <item>
            <title>Cardiac resynchronization therapy: the issue of non-response</title>
            <link>http://www.medworm.com/index.php?rid=4782298&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F46t4kq51j1j3970r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac resynchronization therapy reduces mortality and morbidity in heart failure patients with wide QRS and severe impairment
 of left ventricular systolic function, who are symptomatic despite optimal medical therapy. However, a high percentage of
 patients fail to show clinical or echocardiographic response to this treatment. Beyond current selection criteria, other elements,
 such as QRS duration and morphology, concomitant medical therapy, degree of right ventricle dysfunction, myocardial viability,
 presence of left ventricular dyssynchrony, and associated renal dysfunction, play a crucial role in modulating the response
 to cardiac resynchronization. Consequently, they should be part of the standard pre-implant evaluation, as they could be used
 to identify pati...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4782298</comments>
            <pubDate>Sun, 01 May 2011 15:32:30 +0100</pubDate>
            <guid isPermaLink="false">4782298</guid>        </item>
        <item>
            <title>The paradox of low BNP levels in obesity</title>
            <link>http://www.medworm.com/index.php?rid=4771850&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqmw85516246142g7%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this review is to analyze in detail some possible pathophysiological mechanisms linking obesity and cardiac endocrine
 function, in order to try to explain the negative association previously observed between BMI and BNP values in both healthy
 subjects and patients with cardiovascular diseases. In particular, we discuss the hypothesis that the response of the cardiac
 endocrine system is the integrated resultant of several and contrasting physiological and pathological interactions, including
 the effects of peptide and steroid hormones, cytokines, cardiovascular hemodynamics, clinical conditions, and pharmacological
 treatment. Several studies suggested that gonadal function regulates both body fat distribution and cardiac endocrine function.
 Visceral fat ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4771850</comments>
            <pubDate>Tue, 26 Apr 2011 20:57:12 +0100</pubDate>
            <guid isPermaLink="false">4771850</guid>        </item>
        <item>
            <title>The potential application of electrophysiology diagnostics and therapeutics in acute heart failure syndromes</title>
            <link>http://www.medworm.com/index.php?rid=4771851&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl77l755636172782%2F</link>
            <description>Content Type Journal ArticlePages 1-3DOI 10.1007/s10741-011-9247-1Authors
		Norman C. Wang, Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USAGregg C. Fonarow, Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, CA, USAMihai Gheorghiade, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 1006, Chicago, IL 60611, USA
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4771851</comments>
            <pubDate>Mon, 25 Apr 2011 16:41:27 +0100</pubDate>
            <guid isPermaLink="false">4771851</guid>        </item>
        <item>
            <title>Loop diuretics in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4754895&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa158p430485631g8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Congestion is a major component of the clinical syndrome of heart failure, and diuretic therapy remains the cornerstone of
 congestion management. Despite being widely used, there is very limited evidence from prospective randomized studies to guide
 the prescription and titration of diuretics. A thorough understanding of the pharmacology of loop diuretics is crucial to
 the optimal use of these agents. Although multiple observational studies have suggested that high doses of diuretics may be
 harmful, all such analyses are confounded by the association of higher diuretic doses with greater severity of illness and
 comorbidity. Recent data from randomized trials suggest that higher doses of diuretics may be more effective at relieving
 congestion and that associated cha...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4754895</comments>
            <pubDate>Fri, 22 Apr 2011 16:02:22 +0100</pubDate>
            <guid isPermaLink="false">4754895</guid>        </item>
        <item>
            <title>Managing patients with ICD shocks and programming tachycardia therapies during acute heart failure syndromes</title>
            <link>http://www.medworm.com/index.php?rid=4671495&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdu23v35250h33lr0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We review the pharmacologic, interventional and device programming treatment options for patients with implantable cardioverter-defibrillators
 who present with acute heart failure and implantable cardioverter-defibrillator shocks.
 
 
	Content Type Journal ArticlePages 1-8DOI 10.1007/s10741-011-9241-7Authors
		Jason Bradfield, UCLA Cardiac Arrhythmia Center, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine at UCLA, A2-237 CHS, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1679, USARoderick Tung, UCLA Cardiac Arrhythmia Center, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine at UCLA, A2-237 CHS, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1679, USANoel G. Boyle, UCLA Cardiac Arrhythmia Center, Ronald Reagan UCLA...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4671495</comments>
            <pubDate>Wed, 30 Mar 2011 23:54:41 +0100</pubDate>
            <guid isPermaLink="false">4671495</guid>        </item>
        <item>
            <title>Atrioventricular and interventricular delay optimization in cardiac resynchronization therapy: physiological principles and overview of available methods</title>
            <link>http://www.medworm.com/index.php?rid=4644104&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd51j13r1j4h1445m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In this review, the physiological rationale for atrioventricular and interventricular delay optimization of cardiac resynchronization
 therapy is discussed including the influence of exercise and long-term cardiac resynchronization therapy. The broad spectrum
 of both invasive and non-invasive optimization methods is reviewed with critical appraisal of the literature. Although the
 spectrum of both invasive and non-invasive optimization methods is broad, no single method can be recommend for standard practice
 as large-scale studies using hard endpoints are lacking. Current efforts mainly investigate optimization during resting conditions;
 however, there is a need to develop automated algorithms to implement dynamic optimization in order to adapt to physiological
 alte...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644104</comments>
            <pubDate>Wed, 23 Mar 2011 16:57:28 +0100</pubDate>
            <guid isPermaLink="false">4644104</guid>        </item>
        <item>
            <title>The potential role of cardiac resynchronization therapy in acute heart failure syndromes</title>
            <link>http://www.medworm.com/index.php?rid=4637005&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcnv9k5554mn66362%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac resynchronization therapy (CRT) has been demonstrated to improve mortality and morbidity in patients with chronic,
 stable heart failure who have reduced left ventricular ejection fraction and prolonged QRS duration. Patients with acute heart
 failure syndromes (AHFS) have been excluded from major CRT trials. The potential benefits and risks of implementation of these
 devices in the AHFS setting are largely unknown. In this review, we discuss the role that early implementation of CRT may
 have in improving postdischarge outcomes. In addition, we also discuss the potential adverse consequences of inserting these
 devices in patients who are in the tenuous clinical state of AHFS.
 
 
	Content Type Journal ArticlePages 1-10DOI 10.1007/s10741-011-9237-3Authors
		No...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4637005</comments>
            <pubDate>Tue, 22 Mar 2011 18:11:03 +0100</pubDate>
            <guid isPermaLink="false">4637005</guid>        </item>
        <item>
            <title>Cystatin C: a step forward in assessing kidney function and cardiovascular risk</title>
            <link>http://www.medworm.com/index.php?rid=4637004&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5x66717412745071%2F</link>
            <description>In conclusion, CysC appears to be an interesting marker of renal function
 and is useful for risk stratification in heart failure.
 
 
	Content Type Journal ArticlePages 1-11DOI 10.1007/s10741-011-9242-6Authors
		Johan Lassus, Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, FinlandVeli-Pekka Harjola, Division of Emergency Care, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4637004</comments>
            <pubDate>Tue, 22 Mar 2011 18:11:03 +0100</pubDate>
            <guid isPermaLink="false">4637004</guid>        </item>
        <item>
            <title>Atrioventricular junction ablation and pacemaker implantation for heart failure associated with atrial fibrillation: potential issues and therapies in the setting of acute heart failure syndrome</title>
            <link>http://www.medworm.com/index.php?rid=4632269&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh156722716884244%2F</link>
            <description>This article
 reviews the technique, complications, outcome data, and alternatives to this management strategy. The potential role of this
 therapeutic modality in those hospitalized with acute heart failure syndromes is discussed.
 
 
	Content Type Journal ArticlePages 1-9DOI 10.1007/s10741-011-9238-2Authors
		Jason C. Rubenstein, Department of Medicine, Division of Cardiovascular Medicine, Froedtert East Clinics, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USAJames A. Roth, Department of Medicine, Division of Cardiovascular Medicine, Froedtert East Clinics, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4632269</comments>
            <pubDate>Mon, 21 Mar 2011 19:00:22 +0100</pubDate>
            <guid isPermaLink="false">4632269</guid>        </item>
        <item>
            <title>Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions</title>
            <link>http://www.medworm.com/index.php?rid=4632270&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1w12l10861v4g144%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Implantable cardioverter-defibrillators have proven efficacy in reducing mortality in patients with reduced left ventricular
 ejection fraction in both the primary and the secondary prevention settings. All randomized trials demonstrating this benefit
 have been conducted in outpatients with stable heart failure symptoms. Whether implantable cardioverter-defibrillators confer
 a benefit when implemented in patients with chronically reduced left ventricular ejection fraction in the acute heart failure
 setting is unknown. The purpose of this document is to review the existing literature related to this subject.
 
 
	Content Type Journal ArticlePages 1-4DOI 10.1007/s10741-011-9243-5Authors
		Norman C. Wang, Cardiovascular Institute, University of Pittsburgh Medical Center...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4632270</comments>
            <pubDate>Mon, 21 Mar 2011 19:00:20 +0100</pubDate>
            <guid isPermaLink="false">4632270</guid>        </item>
        <item>
            <title>Device monitoring strategies in acute heart failure syndromes</title>
            <link>http://www.medworm.com/index.php?rid=4623134&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx1kr270274k53g11%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Acute heart failure syndromes (AHFS) represent the most common discharge diagnoses in adults over age 65 and translate into
 dramatically increased heart failure–associated morbidity and mortality. Conventional approaches to the early detection of
 pulmonary and systemic congestion have been shown to be of limited sensitivity. Despite their proven efficacy, disease management
 and structured telephone support programs have failed to achieve widespread use in part due to their resource intensiveness
 and reliance upon motivated patients. While once thought to hold great promise, results from recent prospective studies on
 telemonitoring strategies have proven disappointing. Implantable devices with their capacity to monitor electrophysiologic
 and hemodynamic parameter...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4623134</comments>
            <pubDate>Sat, 19 Mar 2011 02:54:01 +0100</pubDate>
            <guid isPermaLink="false">4623134</guid>        </item>
        <item>
            <title>Assessing patients for catheter ablation during hospitalization for acute heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4611460&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fmw063236214275n5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart rhythm problems are common among patients who are hospitalized with acute heart failure (HF). Although it is often difficult
 to determine whether a tachyarrhythmia is the major contributor to an acute HF decompensation or merely a consequence of the
 decompensation, both issues usually need to be addressed. There is also a subset of patients with HF who have a tachycardia-induced
 cardiomyopathy (TIC), where the sole cause of the ventricular dysfunction is the heart rhythm problem. In most cases, the
 management of a tachyarrhythmia in a patient with acute HF is not significantly different than the management of a heart rhythm
 problem in any patient, but there are several special clinical scenarios and important considerations. These considerations
 include the ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4611460</comments>
            <pubDate>Tue, 15 Mar 2011 17:24:20 +0100</pubDate>
            <guid isPermaLink="false">4611460</guid>        </item>
        <item>
            <title>Pharmacological therapies for the prevention of acute kidney injury following cardiac surgery: a systematic review</title>
            <link>http://www.medworm.com/index.php?rid=4594127&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff1683611w8425725%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Post-cardiac surgery acute kidney injury (AKI) is common and is associated with a significant increase in morbidity and mortality.
 We aimed to systematically review randomised trials that assessed the renoprotective utility of pharmacological agents in
 patients undergoing cardiac surgery. We searched PubMed, Embase and the Cochrane Central Register of Controlled Trials for
 randomised controlled trials comparing renoprotective pharmacological interventions with control in adult patients undergoing
 cardiac surgery with cardiopulmonary bypass. We extracted data for mortality, need for renal replacement therapy (RRT), incidence
 of AKI, and creatinine clearance at 24–48&amp;nbsp;h. About 49 randomised controlled trials involving 4605 patients were included.
 Pharmacologic...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4594127</comments>
            <pubDate>Sat, 12 Mar 2011 16:53:12 +0100</pubDate>
            <guid isPermaLink="false">4594127</guid>        </item>
        <item>
            <title>Strategies for pacemaker programming in acute heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4594128&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx72743181n438454%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In the past decade, cardiac pacing devices (either permanent pacemakers or Implanted Cardioverter Defibrillators) have become
 increasingly common in patients with heart failure. The manner in which the device is programmed to pace the heart can have
 significant implications on cardiac hemodynamics, both positive and negative. As such, in patients hospitalized with acute
 heart failure who have cardiac pacing devices, the clinician should note whether the programming of the device could be contributing
 to the patient’s symptoms, and whether further programming changes could be made to improve the patient’s clinical status.
 As of this date, there are no consensus guidelines available for the management of pacemaker programming in acute heart failure.
 This review ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4594128</comments>
            <pubDate>Sat, 12 Mar 2011 16:53:11 +0100</pubDate>
            <guid isPermaLink="false">4594128</guid>        </item>
        <item>
            <title>Erratum to: Resveratrol and red wine, healthy heart and longevity</title>
            <link>http://www.medworm.com/index.php?rid=4594129&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F68u122455731n771%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Resveratrol, a polyphenol phytoalexin, present in red wine and grapes possesses diverse biochemical and physiological properties,
 including estrogenic, antiplatelet, and anti-inflammatory properties as well as a wide range of health benefits ranging from
 chemoprevention to cardioprotection. Recently, several studies described resveratrol as an anti-aging compound. This review
 focuses on the anti-aging aspects of resveratrol, the possible mechanisms of action, and emerging controversy on its life-prolonging
 ability. It appears that resveratrol can induce the expression of several longevity genes including Sirt1, Sirt3, Sirt4, FoxO1, Foxo3a and PBEF and prevent aging-related decline in cardiovascular function including cholesterol level and inflammatory response, but ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4594129</comments>
            <pubDate>Sat, 12 Mar 2011 07:01:27 +0100</pubDate>
            <guid isPermaLink="false">4594129</guid>        </item>
        <item>
            <title>A re-appraisal of volume status and renal function impairment in chronic heart failure: combined effects of pre-renal failure and venous congestion on renal function</title>
            <link>http://www.medworm.com/index.php?rid=4550230&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh0037565h374x703%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The association between cardiac failure and renal function impairment has gained wide recognition over the last decade. Both
 structural damage in the form of systemic atherosclerosis and (patho) physiological hemodynamic changes may explain this association.
 As regards hemodynamic factors, renal impairment in chronic heart failure is traditionally assumed to be mainly due to a decrease
 in cardiac output and a subsequent decrease in renal perfusion. This will lead to a decrease in glomerular filtration rate
 and a compensatory increase in tubular sodium retention. The latter is a physiological renal response aimed at retaining fluids
 in order to increase cardiac filling pressure and thus renal perfusion. In heart failure, however, larger increases in cardiac
 filling...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4550230</comments>
            <pubDate>Wed, 02 Mar 2011 06:59:22 +0100</pubDate>
            <guid isPermaLink="false">4550230</guid>        </item>
        <item>
            <title>Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms</title>
            <link>http://www.medworm.com/index.php?rid=4502681&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F841641775h8532n4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Anemia is a disease that is often associated with heart failure (HF) and renal insufficiency (RI). This unfavorable triad
 of conditions has been called Cardio-Renal-Anemia Syndrome (CRS). The association of HF, RI, and anemia is poorly reported
 in multicenter clinical trials, so the pathophysiologic mechanisms and treatment options need to be better defined. When CRS
 patients develop anemia, a “perfect storm” often occurs: HF and RI cause anemia which will worsen the first two conditions.
 Anemia appears to be the result of complex interactions between cardiac performance, bone marrow homeostasis, renal dysfunction,
 and various drug side effects. However, neurohormonal and inflammatory activities play a key role in the beginning and progression
 of the disease. ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4502681</comments>
            <pubDate>Fri, 18 Feb 2011 17:23:39 +0100</pubDate>
            <guid isPermaLink="false">4502681</guid>        </item>
        <item>
            <title>Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes</title>
            <link>http://www.medworm.com/index.php?rid=4495954&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4j517p5223251157%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Over the last decade, it has become increasingly clear that the cardiovascular and renal systems are interdependent. Primary
 disorders of either system have been shown to disturb the other system. As a result, a class of cardiorenal syndromes (CRS)
 has been identified wherein a vicious cycle is established as an acute/chronic dysfunction of either the kidney or the heart
 exacerbates the loss of function in the other organ. Progressive loss of kidney function observed in patients with CRS (mostly
 types 2 and 4) leads to reduced production of calcitriol (active vitamin D) and an imbalance in calcium and phosphorus levels,
 which are correlated with increased rates of cardiovascular events and mortality. In addition, hypocalcemia can lead to prolonged
 and excessive se...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4495954</comments>
            <pubDate>Wed, 16 Feb 2011 06:56:17 +0100</pubDate>
            <guid isPermaLink="false">4495954</guid>        </item>
        <item>
            <title>Management and monitoring of haemodynamic complications in acute heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4460803&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl65272x143627760%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The pathophysiology of acute heart failure syndromes (AHFS), defined as a change or worsening in heart failure symptoms and
 signs, is complex. The variety of adverse neurohormonal adaptations includes increased levels of plasma renin, aldosterone
 and angiotensin II, all responsible for cardio-renal dysfunction. In fact, such alterations result in an array of clinical
 changes that include abnormal haemodynamics, altered ventricular filling pressures, pathological neurohormonal responses,
 leading to fluid overload, congestion and ultimately heart failure symptoms. Clinical pictures can be various: in spite of
 a usual improvement in dyspnoea, little weight change and significant morbidity are generally observed during hospitalization.
 Short-term outcomes are characte...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4460803</comments>
            <pubDate>Mon, 07 Feb 2011 22:57:57 +0100</pubDate>
            <guid isPermaLink="false">4460803</guid>        </item>
        <item>
            <title>Laboratory parameters of cardiac and kidney dysfunction in cardio-renal syndromes</title>
            <link>http://www.medworm.com/index.php?rid=4442701&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9pmh726876332432%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;“Cardio-Renal Syndromes” (CRS) are disorders of the heart and kidneys in which acute or chronic dysfunction in one organ may
 induce acute or chronic dysfunction of the other. The pathophysiology of CRS is complex, and there is accumulating evidence
 that various novel biomarkers are useful for diagnosis, prognostication, and risk stratification in patients with heart failure
 and chronic kidney disease (CRS). When both the heart failure (HF) and CKD occur together, it is important to have biomarkers
 that are able to risk stratify patients by looking at both their heart and kidney aspects. There are some promising newer
 renal biomarkers that may contribute to a better evaluation and prediction of prognosis in CRS patients. Most of the renal
 biomarkers studies in ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4442701</comments>
            <pubDate>Fri, 04 Feb 2011 17:48:23 +0100</pubDate>
            <guid isPermaLink="false">4442701</guid>        </item>
        <item>
            <title>Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies</title>
            <link>http://www.medworm.com/index.php?rid=4442702&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr042v4p6v5uj7r76%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic heart failure (CHF) is characterized by decreased nitric oxide (NO) bioavailability. In addition, the beneficial NO
 turns to be deleterious when it reacts with superoxide anion, leading to peroxynitrite formation. Numerous experimental and
 clinical studies have reported increased production of reactive oxygen species (superoxide, hydrogen peroxide, hydroxyl radical)
 both in animals and patients with CHF. Moreover, there are indicative data suggesting mechanisms associated with endothelial
 dysfunction in states of CHF, mainly attributed to decreased NO bioavailability and enhanced inactivation of the latter. Thus,
 such molecules appear to be potential targets in patients with CHF. These patients are strong candidates to receive a variety
 of therapeutic agen...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4442702</comments>
            <pubDate>Fri, 04 Feb 2011 03:35:25 +0100</pubDate>
            <guid isPermaLink="false">4442702</guid>        </item>
        <item>
            <title>Erratum to: Mechano-energetics of the asynchronous and resynchronized heart</title>
            <link>http://www.medworm.com/index.php?rid=4415401&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk1hp1672l8344175%2F</link>
            <description>Content Type Journal ArticlePages 1-1DOI 10.1007/s10741-011-9227-5Authors
		Frits W. Prinzen, Departments of Physiology, Cardiology and Biomedical Engineering, Cardiovascular Research Institute Maastricht, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The NetherlandsKevin Vernooy, Departments of Physiology, Cardiology and Biomedical Engineering, Cardiovascular Research Institute Maastricht, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The NetherlandsBart W. L. De Boeck, University Hospital Basel, Basel, SwitzerlandTammo Delhaas, Departments of Physiology, Cardiology and Biomedical Engineering, Cardiovascular Research Institute Maastricht, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-73...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4415401</comments>
            <pubDate>Thu, 27 Jan 2011 10:02:33 +0100</pubDate>
            <guid isPermaLink="false">4415401</guid>        </item>
        <item>
            <title>Cardio-renal syndromes: from foggy bottoms to sunny hills</title>
            <link>http://www.medworm.com/index.php?rid=4400798&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7104827822651607%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;“Cardio-renal syndromes” (CRS) are disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may
 induce acute or chronic dysfunction of the other. The current definition has been expanded into five subtypes whose etymology
 reflects the primary and secondary pathology, the time-frame and simultaneous cardiac and renal co-dysfunction secondary to
 systemic disease: CRS type I: acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. CRS
 type II: chronic abnormalities in heart function (CHF-CHD) leading to kidney injury or dysfunction. CRS type III: acute worsening
 of kidney function (AKI) leading to heart injury and/or dysfunction. CRS type IV: chronic kidney disease (CKD) leading to
 heart injury, disease...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4400798</comments>
            <pubDate>Sat, 22 Jan 2011 20:14:33 +0100</pubDate>
            <guid isPermaLink="false">4400798</guid>        </item>
        <item>
            <title>Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome</title>
            <link>http://www.medworm.com/index.php?rid=4400799&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx542680812410519%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The prevalence of heart failure (HF) is increasing. A distinction is made between diastolic HF (preserved left ventricular
 ejection fraction (LVEF)) and systolic HF (reduced LVEF). Advanced glycation end-products (AGEs) are crystallized proteins
 that accumulate during ageing, but are particularly increased in patients with diabetes mellitus and in patients with renal
 failure. Through the formation of collagen crosslinks, and by interaction with the AGE-receptor, which impairs calcium handling
 and increases fibrosis, AGE-accumulation has pathophysiologically been associated with the development of diastolic and renal
 dysfunction. Interestingly, diastolic dysfunction is a frequent finding in elderly patients, diabetic patients and in patients
 with renal failure. Tak...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4400799</comments>
            <pubDate>Sat, 22 Jan 2011 20:14:32 +0100</pubDate>
            <guid isPermaLink="false">4400799</guid>        </item>
        <item>
            <title>Current and future role of cardiovascular magnetic resonance in cardiac resynchronization therapy</title>
            <link>http://www.medworm.com/index.php?rid=4322937&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc33g37411855m28u%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac resynchronization therapy (CRT) has revolutionized the treatment of selected patients with systolic heart failure.
 It is well recognized, however, that the symptomatic response to and the outcome of CRT is highly variable. The degree of
 pre-implant mechanical dyssynchrony and the extent as well as the localization of myocardial scarring are known to contribute
 to this variability. Cardiovascular magnetic resonance (CMR) is the gold-standard imaging modality for the assessment of myocardial
 structure and function. Recently, CMR has also been shown to be useful in assessing cardiac dyssynchrony and in guiding left
 ventricular lead deployment away from scarred myocardium. This review explores the current role of CMR in risk stratification
 and in guiding LV le...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4322937</comments>
            <pubDate>Wed, 05 Jan 2011 16:51:10 +0100</pubDate>
            <guid isPermaLink="false">4322937</guid>        </item>
        <item>
            <title>Cardio-renal syndromes: a systematic approach for consensus definition and classification</title>
            <link>http://www.medworm.com/index.php?rid=4303211&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdx74383345755160%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The “Cardio-Renal Syndrome” (CRS) is a disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction
 of the other. The general definition has been expanded to five subtypes reflecting the primacy of organ dysfunction and the
 time-frame of the syndrome: CRS type I: acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction.
 CRS type II: chronic abnormalities in heart function (CHF-CHD) leading to kidney injury or dysfunction. CRS type III: acute
 worsening of kidney function (AKI) leading to heart injury and/or dysfunction. CRS type IV: chronic kidney disease (CKD) leading
 to heart injury, disease and/or dysfunction. CRS type V: systemic conditions leading to simultaneous i...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4303211</comments>
            <pubDate>Fri, 31 Dec 2010 18:03:12 +0100</pubDate>
            <guid isPermaLink="false">4303211</guid>        </item>
        <item>
            <title>Epidemiology and outcome of the cardio-renal syndrome</title>
            <link>http://www.medworm.com/index.php?rid=4302377&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3787q2863r05700h%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac and kidney disease are common, increasingly encountered and often co-exist. Recently, the Acute Dialysis Quality Initiative
 (ADQI) Working Group convened a consensus conference to develop a classification scheme for the CRS and for five discrete
 subtypes. These CRS subtypes likely share pathophysiologic mechanisms, however, also have distinguishing clinical features,
 in terms of precipitating events, risk identification, natural history and outcomes. Knowledge of the epidemiology of heart–kidney
 interaction stratified by the proposed CRS subtypes is increasingly important for understanding the overall burden of disease
 for each CRS subtype, along with associated morbidity, mortality and health resource utilization. Likewise, an understanding
 of the epide...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4302377</comments>
            <pubDate>Thu, 30 Dec 2010 18:04:34 +0100</pubDate>
            <guid isPermaLink="false">4302377</guid>        </item>
        <item>
            <title>The vagus nerve and autonomic imbalance in heart failure: past, present, and future</title>
            <link>http://www.medworm.com/index.php?rid=4300996&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9r57p681ht228937%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s10741-010-9222-2Authors
		Paul J. Hauptman, Department of Medicine, Saint Louis University School of Medicine, St. Louis, MO USADouglas L. Mann, Department of Medicine, Washington University School of Medicine, St. Louis, MO USA
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4300996</comments>
            <pubDate>Wed, 29 Dec 2010 17:12:19 +0100</pubDate>
            <guid isPermaLink="false">4300996</guid>        </item>
        <item>
            <title>Lead positioning strategies to enhance response to cardiac resynchronization therapy</title>
            <link>http://www.medworm.com/index.php?rid=4289147&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv281747q680x0060%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Left ventricular lead position is one of the main determinants of CRT response. There are several approaches in LV lead positioning
 that include favoring an optimal anatomical position or targeting either the segment with maximal mechanical dyssynchrony
 or a region with maximal electrical delay. The conventional LV lead implantation faces several technical difficulties that
 may prevent the obtaining of a stable position and good performance of the LV lead without phrenic nerve stimulation. In addition,
 implant of the LV pacing lead in areas with myocardial scar may result in less than optimal cardiac resynchronization. Several
 strategies have been proposed to overcome all these obstacles including multimodality cardiac imaging to help in preprocedural
 or intraproc...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4289147</comments>
            <pubDate>Thu, 23 Dec 2010 17:49:55 +0100</pubDate>
            <guid isPermaLink="false">4289147</guid>        </item>
        <item>
            <title>The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy</title>
            <link>http://www.medworm.com/index.php?rid=4272817&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu085vpkrt0242340%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiovascular magnetic resonance imaging (CMR) plays an increasing role in the assessment of patients with various cardiovascular
 disorders. Given its enhanced spatial resolution, improved tissue characterization, and lack of ionizing radiation, it has
 become the test of choice in the evaluation of patients with new-onset cardiomyopathy of unknown etiology. In this paper,
 we will review the role of CMR in the evaluation of patients with various types of non-ischemic cardiomyopathy.
 
 
	Content Type Journal ArticleDOI 10.1007/s10741-010-9221-3Authors
		Mouaz H. Al-Mallah, King Abdul-Aziz Cardiac Center, King Abdul-Aziz Medical City, Department Mail Code 1413, P.O. Box 22490, Riyadh, 11426 Kingdom of Saudi ArabiaMohammad Naseem Shareef, King Abdul-Aziz Cardiac Center...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4272817</comments>
            <pubDate>Fri, 17 Dec 2010 17:40:44 +0100</pubDate>
            <guid isPermaLink="false">4272817</guid>        </item>
        <item>
            <title>Role of multimodality imaging in ischemic and non-ischemic cardiomyopathy</title>
            <link>http://www.medworm.com/index.php?rid=4272818&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F03tx4500867gj781%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic heart failure (CHF) is a major and growing problem in the western hemisphere, affecting about 5&amp;nbsp;million patients in
 the United States. In daily practice patients with left ventricular systolic dysfunction (LVSD) and significant angiographic
 coronary artery disease (CAD) are felt to have an ischemic cardiomyopathy (ICMP) and those without CAD or mild–moderate CAD
 out of proportion to the extent of LVSD are felt to have a non-ischemic cardiomyopathy (NICMP). Although invasive coronary
 angiography is the gold standard for the diagnosis of CAD, recent advances in non-invasive imaging have created multiple options
 for evaluating ICMP and NICMP. This review details the role of cardiac imaging in the diagnosis of ICMP and NICMP and outlines
 an algorithm of...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4272818</comments>
            <pubDate>Fri, 17 Dec 2010 06:52:41 +0100</pubDate>
            <guid isPermaLink="false">4272818</guid>        </item>
        <item>
            <title>Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions</title>
            <link>http://www.medworm.com/index.php?rid=4272819&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ffpq0k5n56q768349%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Vagus nerve stimulation was performed experimentally for the first time more than 150&amp;nbsp;years ago. In the 1980s and 1990s, vagus
 nerve stimulation was shown, both in the anesthetized and in the conscious animal, to exert marked antiarrhythmic effects,
 particularly during acute myocardial ischemia. There is a strong rationale for a beneficial effect of augmented vagal activity
 in the setting of chronic heart failure. Studies in experimental models of heart failure showed that chronic vagus nerve stimulation
 exerts beneficial effects on left ventricular function and on survival. Vagus nerve stimulation is approved in man for refractory
 epilepsy and depression. The first-in-man study performed in 32 patients with chronic heart failure suggests that vagus nerve
 sti...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4272819</comments>
            <pubDate>Fri, 17 Dec 2010 06:52:39 +0100</pubDate>
            <guid isPermaLink="false">4272819</guid>        </item>
        <item>
            <title>Chronic Chagas’ heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine</title>
            <link>http://www.medworm.com/index.php?rid=4272820&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx41382k3t6820480%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chagas’ disease, caused by Trypanosoma cruzi infection, is ranked as the most serious parasitic disease in Latin America. Nearly 30% of infected patients develop life-threatening
 complications, and with a latency of 10–30&amp;nbsp;years, mostly Chagas’ heart disease which is currently the major cause of morbidity
 and mortality in Latin America, enormously burdening economic resources and dramatically affecting patients’ social and labor
 situations. Because of increasing migration, international tourism and parasite transfer by blood contact, intrauterine transfer
 and organ transplantation, Chagas’ heart disease could potentially become a worldwide problem. To raise awareness of this
 problem, we reflect on the epidemiology and etiopathology of Chagas’ diseas...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4272820</comments>
            <pubDate>Fri, 17 Dec 2010 06:52:38 +0100</pubDate>
            <guid isPermaLink="false">4272820</guid>        </item>
        <item>
            <title>The diastolic stress test: a new approach to an old problem</title>
            <link>http://www.medworm.com/index.php?rid=4272821&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2461176wt1268g07%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The evaluation of ischemic heart disease is the cornerstone of clinical Cardiology. Although there are many means of ischemic
 evaluation, all are with their own limitations. While perfusion-based studies are highly sensitive, they lack specificity.
 Conversely, systolic wall motion analysis with echocardiography tends to have high specificity; however, the sensitivity may
 be limited by short duration of systolic abnormalities when present. With the advent of Doppler echocardiography, and more
 specifically tissue Doppler imaging, and strain and strain rate imaging, a more comprehensive evaluation of the left ventricular
 function is available, including diastole. Diastolic abnormalities in the setting of ischemia are now being studied using
 these new parameters and h...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4272821</comments>
            <pubDate>Thu, 16 Dec 2010 06:53:54 +0100</pubDate>
            <guid isPermaLink="false">4272821</guid>        </item>
        <item>
            <title>Novel techniques for assessment of left ventricular systolic function</title>
            <link>http://www.medworm.com/index.php?rid=4267298&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv42056h467x35157%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The evaluation of left ventricular systolic function is one of the most common reasons for referral for a non-invasive cardiac
 imaging study. In addition to its diagnostic and prognostic value, an assessment of ejection fraction can also be used to
 guide medical and device therapy. Thus, obtaining an accurate and reproducible assessment of LVEF is essential for patient
 management. This review will focus on novel multi-modality techniques used for the quantification of left ventricular systolic
 function. Emerging echocardiography techniques such as three-dimensional echocardiography and strain imaging and their incremental
 role over traditional 2D imaging will be discussed. In addition, new developments expanding nuclear imaging techniques’ evaluation
 of left ven...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4267298</comments>
            <pubDate>Tue, 14 Dec 2010 06:41:09 +0100</pubDate>
            <guid isPermaLink="false">4267298</guid>        </item>
        <item>
            <title>A practical approach to imaging dyssynchrony for cardiac resynchronization therapy</title>
            <link>http://www.medworm.com/index.php?rid=4249632&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff11t3611160r10tr%2F</link>
            <description>This article will review the principal echocardiographic methods of dyssynchrony analysis by tissue Doppler imaging, (opposing
 wall delay, 12-site standard deviation or Yu index, and longitudinal strain), routine pulsed-Doppler (interventricular mechanical
 delay, pre-ejection delay and filling time ratio), and speckle tracking (including radial, circumferential, and longitudinal
 strain). In addition, dyssynchrony analysis by cardiac magnetic resonance imaging is introduced as a potential alternative
 technique. The technical features, strengths and limitations, and clinical evidence for these methods are discussed, including
 a practical clinical approach.
 
 
	Content Type Journal ArticlePages 1-14DOI 10.1007/s10741-010-9220-4Authors
		Olusegun A. Oyenuga, University of Pittsburgh, Sca...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4249632</comments>
            <pubDate>Wed, 08 Dec 2010 18:13:25 +0100</pubDate>
            <guid isPermaLink="false">4249632</guid>        </item>
        <item>
            <title>Current treatment in acute and chronic cardio-renal syndrome</title>
            <link>http://www.medworm.com/index.php?rid=4242513&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff32x616755454100%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardio-renal syndrome (CRS) is a renal dysfunction occurring in a large percentage of patients hospitalized with congestive
 heart failure (HF). Cardiac and renal dysfunctions often occur simultaneously because they share causes and pathogenetic mechanisms.
 Current therapies for HF are focused on improving myocardial function and hemodynamic balance, but may have potential consequences
 for worsening renal function. The lack of specific trials in this field highlights the need for further studies aimed to assess
 efficacy and safety, titration and appropriate dosages of drugs, according to the etiology and severity of both myocardial
 and renal dysfunction. Moreover, the most recent clinical trials evaluating new drugs on clinical and renal outcome in acute
 heart fail...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4242513</comments>
            <pubDate>Mon, 06 Dec 2010 18:47:38 +0100</pubDate>
            <guid isPermaLink="false">4242513</guid>        </item>
        <item>
            <title>Past, present, and future of CRT</title>
            <link>http://www.medworm.com/index.php?rid=4242514&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx0w24n2jw66317x8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac resynchronization therapy is a key non-pharmacological treatment strategy for drug-refractory moderate-to-severe symptomatic
 heart failure in the presence of compromised left ventricular function and ventricular conduction delay. Because not all patients
 with conventional criteria benefit from CRT, continuous efforts have been directed toward improving patient selection; in
 particular, emerging echocardiographic criteria such as regional and global myocardial strains are being investigated to better
 predict CRT response. In the meantime, growing evidence from large randomized controlled trials (RCTs, REVERSE, and MADIT-CRT)
 has demonstrated that even mildly symptomatic patients may benefit from CRT. The role of CRT in heart failure patients with
 narrow QRS...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4242514</comments>
            <pubDate>Mon, 06 Dec 2010 15:07:38 +0100</pubDate>
            <guid isPermaLink="false">4242514</guid>        </item>
        <item>
            <title>Vagus nerve stimulation in experimental heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4230829&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2445451042065784%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic heart failure (HF) is associated with autonomic dysregulation characterized by a sustained increase in sympathetic
 drive and by withdrawal of parasympathetic activity. Sympathetic overdrive and increased heart rate are predictors of poor
 long-term outcome in patients with HF. Considerable evidence exists that supports the use of pharmacologic agents that partially
 inhibit sympathetic activity as effective long-term therapy for patients with HF; the classic example is the wide use of selective
 and non-selective beta-adrenergic receptor blockers. In contrast, modulation of parasympathetic activation as potential therapy
 for HF has received only limited attention over the years given its complex cardiovascular effects. In this article, we review
 the results o...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4230829</comments>
            <pubDate>Thu, 02 Dec 2010 18:14:34 +0100</pubDate>
            <guid isPermaLink="false">4230829</guid>        </item>
        <item>
            <title>Hypertension, left ventricular hypertrophy and chronic kidney disease</title>
            <link>http://www.medworm.com/index.php?rid=4225904&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2g22660792115323%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Left ventricular hypertrophy (LVH) is a cardiovascular complication highly prevalent in patients with chronic kidney disease
 (CKD) and end-stage renal disease. LVH in CKD patients has generally a negative prognostic value, because it represents an
 independent risk factor for the development of arrhythmias, sudden death, heart failure and ischemic heart disease. LVH in
 CKD patients is secondary to both pressure and volume overload. Pressure overload is secondary to preexisting hypertension,
 but also to a loss of elasticity of the vessels and to vascular calcifications, leading to augmented pulse pressure. Anemia
 and the retention of sodium and water secondary to decreased renal function are responsible for volume overload, determining
 a hyperdynamic state. In parti...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4225904</comments>
            <pubDate>Tue, 30 Nov 2010 07:04:28 +0100</pubDate>
            <guid isPermaLink="false">4225904</guid>        </item>
        <item>
            <title>Arrhythmic complication in cardiorenal syndrome</title>
            <link>http://www.medworm.com/index.php?rid=4225903&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa67q925153216017%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In this paper, two different aspects of the relationship between chronic kidney disease and sudden cardiac death (SCD) have
 been reviewed. In end-stage renal disease patients, SCD risk is increased, and among patients implanted with a cardioverter
 defibrillator (ICD), dialysed ones carry a superior relative risk compared to non-dialysed ones. Cardiorenal syndrome patients
 have increase in SCD risk, and when receiving ICD implantation, survival improves.
 
 
	Content Type Journal ArticleDOI 10.1007/s10741-010-9210-6Authors
		Luigi Padeletti, Istituto di Clinica Medica e Cardiologia, Università degli Studi di Firenze, AUO Careggi, Viale Morgagni 85, 50134 Florence, ItalyLisa Innocenti, Istituto di Clinica Medica e Cardiologia, Università degli Studi di Firenze, AUO C...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4225903</comments>
            <pubDate>Tue, 30 Nov 2010 07:04:28 +0100</pubDate>
            <guid isPermaLink="false">4225903</guid>        </item>
        <item>
            <title>When is an optimization not an optimization? Evaluation of clinical implications of information content (signal-to-noise ratio) in optimization of cardiac resynchronization therapy, and how to measure and maximize it</title>
            <link>http://www.medworm.com/index.php?rid=4206531&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flhmn33747rhq0202%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Impact of variability in the measured parameter is rarely considered in designing clinical protocols for optimization of atrioventricular
 (AV) or interventricular (VV) delay of cardiac resynchronization therapy (CRT). In this article, we approach this question
 quantitatively using mathematical simulation in which the true optimum is known and examine practical implications using some
 real measurements. We calculated the performance of any optimization process that selects the pacing setting which maximizes an underlying signal, such as flow or pressure, in the
 presence of overlying random variability (noise). If signal and noise are of equal size, for a 5-choice optimization (60,
 100, 140, 180, 220&amp;nbsp;ms), replicate AV delay optima are rarely identical but rather...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4206531</comments>
            <pubDate>Thu, 25 Nov 2010 20:09:01 +0100</pubDate>
            <guid isPermaLink="false">4206531</guid>        </item>
        <item>
            <title>Chronic ventricular pacing in children: toward prevention of pacing-induced heart disease</title>
            <link>http://www.medworm.com/index.php?rid=4203742&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff531jm7ku1w19265%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In children with congenital or acquired complete atrioventricular (AV) block, ventricular pacing is indicated to increase
 heart rate. Ventricular pacing is highly beneficial in these patients, but an important side effect is that it induces abnormal
 electrical activation patterns. Traditionally, ventricular pacemaker leads are positioned at the right ventricle (RV). The
 dyssynchronous pattern of ventricular activation due to RV pacing is associated with an acute and chronic impairment of left
 ventricular (LV) function, structural remodeling of the LV, and increased risk of heart failure. Since the degree of pacing-induced
 dyssynchrony varies between the different pacing sites, ‘optimal-site pacing’ should aim at the prevention of mechanical dyssynchrony.
 Espec...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4203742</comments>
            <pubDate>Tue, 23 Nov 2010 18:15:22 +0100</pubDate>
            <guid isPermaLink="false">4203742</guid>        </item>
        <item>
            <title>Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4197828&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc524766006025226%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The prognosis for patients diagnosed with heart failure has significantly improved over the past three decades; however, the
 disease still confers a high degree of morbidity and mortality. Current treatments for chronic heart failure have focused
 primarily on blocking neurohormonal signaling and optimizing hemodynamic parameters. Although significant resources have been
 devoted toward the development of new pharmaceutical therapies for heart failure, few new drugs have been designed to target
 myocardial metabolic pathways despite growing evidence that on a fundamental level chronic heart failure can be characterized
 as an imbalance between myocardial energy demand and supply. Disruptions in myocardial energy pathways are evident as the
 myocardium is unable to gene...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4197828</comments>
            <pubDate>Mon, 22 Nov 2010 16:45:57 +0100</pubDate>
            <guid isPermaLink="false">4197828</guid>        </item>
        <item>
            <title>Electrical modalities beyond pacing for the treatment of heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4197827&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc684872454784r54%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In this review, we report on electrical modalities, which do not fit the definition of pacemaker, but increase cardiac performance
 either by direct application to the heart (e.g., post-extrasystolic potentiation or non-excitatory stimulation) or indirectly
 through activation of the nervous system (e.g., vagal or sympathetic activation). The physiological background of the possible
 mechanisms of these electrical modalities and their potential application to treat heart failure are discussed.
 
 
	Content Type Journal ArticleDOI 10.1007/s10741-010-9206-2Authors
		Richard N. Cornelussen, Research and Technology, Medtronic Bakken Research Center BV, Endepolsdomein 5, 6229 GW Maastricht, The NetherlandsVincent Splett, CRDM, Medtronic Moundsview, Minneapolis, MN USARuth Ni...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4197827</comments>
            <pubDate>Mon, 22 Nov 2010 16:45:57 +0100</pubDate>
            <guid isPermaLink="false">4197827</guid>        </item>
        <item>
            <title>Echocardiographic prediction of outcome after cardiac resynchronization therapy: conventional methods and recent developments</title>
            <link>http://www.medworm.com/index.php?rid=4191541&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1q2292861g4456l5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Echocardiography plays an important role in patient assessment before cardiac resynchronization therapy (CRT) and can monitor
 many of its mechanical effects in heart failure patients. Encouraged by the highly variable individual response observed in
 the major CRT trials, echocardiography-based measurements of mechanical dyssynchrony have been extensively investigated with
 the aim of improving response prediction and CRT delivery. Despite recent setbacks, these techniques have continued to develop
 in order to overcome some of their initial flaws and limitations. This review discusses the concepts and rationale of the
 available echocardiographic techniques, highlighting newer quantification methods and discussing some of the unsolved issues
 that need to be addressed...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191541</comments>
            <pubDate>Sat, 20 Nov 2010 17:51:04 +0100</pubDate>
            <guid isPermaLink="false">4191541</guid>        </item>
        <item>
            <title>Mechano-energetics of the asynchronous and resynchronized heart</title>
            <link>http://www.medworm.com/index.php?rid=4191542&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj36203mk2v3436x1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Abnormal electrical activation of the ventricles creates major abnormalities in cardiac mechanics. Local contraction patterns,
 as reflected by measurements of local strain, are not only out of phase, but often also show opposing length changes in early
 and late activated regions. As a consequence, the efficiency of cardiac pump function (the amount of stroke work generated
 by a unit of oxygen consumed) is approximately 30% lower in asynchronous than in synchronous hearts. Moreover, the amount
 of work performed in myocardial segments becomes considerably larger in late than in early activated regions. Cardiac Resynchronization
 Therapy (CRT) improves mechano-energetics of the previously asynchronous heart in various ways: it alleviates impediment of
 the abnormal con...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191542</comments>
            <pubDate>Fri, 19 Nov 2010 17:03:52 +0100</pubDate>
            <guid isPermaLink="false">4191542</guid>        </item>
        <item>
            <title>Heart failure, diastolic dysfunction and atrial fibrillation; mechanistic insight of a complex inter-relationship</title>
            <link>http://www.medworm.com/index.php?rid=4191543&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh450736h024x2003%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Atrial fibrillation (AF) and heart failure (HF) commonly coexist, and their co-presence is associated with adverse outcomes
 relating to thromboembolic events, HF progression, hospitalisation and death. Diastolic dysfunction (DD) is also frequently
 present in patients with HF and is an independent predictor of hospitalisation and mortality. The presence of DD is a strong
 predictor of incident AF in patients with HF. In this review, we provide mechanistic insight into pathophysiological processes
 that frequently promote the occurrence of AF, HF and DD and outline the yin-yang relationship between AF, DD and HF. More
 recently, invasive studies have also shown that asymptomatic paroxysmal atrial fibrillation (PAF) is a common phenomenon in
 HF patients. We examine comp...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191543</comments>
            <pubDate>Fri, 19 Nov 2010 17:03:50 +0100</pubDate>
            <guid isPermaLink="false">4191543</guid>        </item>
        <item>
            <title>Multimodality imaging in the assessment of myocardial viability</title>
            <link>http://www.medworm.com/index.php?rid=4160013&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3242874543x7234j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The prevalence of heart failure due to coronary artery disease continues to increase, and it portends a worse prognosis than
 non-ischemic cardiomyopathy. Revascularization improves prognosis in these high-risk patients who have evidence of viability;
 therefore, optimal assessment of myocardial viability remains essential. Multiple imaging modalities exist for differentiating
 viable myocardium from scar in territories with contractile dysfunction. Given the multiple modalities available, choosing
 the best modality for a specific patient can be a daunting task. In this review, the physiology of myocardial hibernation
 and stunning will be reviewed. All the current methods available for assessing viability including echocardiography, cardiac
 magnetic resonance imaging...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4160013</comments>
            <pubDate>Wed, 10 Nov 2010 17:27:37 +0100</pubDate>
            <guid isPermaLink="false">4160013</guid>        </item>
        <item>
            <title>The molecular fingerprint of cardiac dyssynchrony and cardiac resynchronization therapy</title>
            <link>http://www.medworm.com/index.php?rid=4109815&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3465q72475132344%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To date, cardiac resynchronization therapy remains the only treatment that enhances systolic function while improving long-term
 outcome and survival. Here, we review the molecular alterations associated with dyssynchronous heart failure and their reversibility
 induced by cardiac resynchronization therapy. We focus upon the molecular portrait of dyssynchronous heart failure and how
 cardiac resynchronization therapy influences electrophysiologic, metabolic and adrenergic pathways.
 
 
	Content Type Journal ArticleDOI 10.1007/s10741-010-9199-xAuthors
		Marc Vanderheyden, Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, BelgiumChris Vrints, Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, BelgiumJozef Bartunek, Cardiovascular Center, Onze Lieve Vrouwzie...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4109815</comments>
            <pubDate>Sun, 24 Oct 2010 05:33:26 +0100</pubDate>
            <guid isPermaLink="false">4109815</guid>        </item>
        <item>
            <title>Current and future role of ultrafiltration in CRS</title>
            <link>http://www.medworm.com/index.php?rid=4100927&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk432643251140960%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ultrafiltration has been used in patients with decompensated HF and volume overload refractory to diuretics. Criteria for
 the initiation of renal replacement therapy (RRT) in the ICU are oliguria, anuria, urea, creatinine, Na and K blood concentrations,
 pulmonary edema unresponsive to diuretics, uncompensated metabolic acidosis, temperature &amp;gt;40°C, uremic complication, and overdose
 with a dialyzable toxin. Moreover, the treatment of acute renal failure requires a different style and philosophy from renal
 replacement therapy for chronic renal failure. The degree and the location of renal lesion, the entity, the gravity of the
 concomitant acute or chronic cardiac damage, the weight of a trauma, surgical stress, or septic complication they determine
 a variability ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4100927</comments>
            <pubDate>Fri, 22 Oct 2010 18:28:33 +0100</pubDate>
            <guid isPermaLink="false">4100927</guid>        </item>
        <item>
            <title>The role of nuclear imaging in the failing heart: myocardial blood flow, sympathetic innervation, and future applications</title>
            <link>http://www.medworm.com/index.php?rid=4068268&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv1u404r160137574%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure represents a common disease affecting approximately 5 million patients in the United States. Several conditions
 play an important role in the development and progression of heart failure, including abnormalities in myocardial blood flow
 and sympathetic innervation. Nuclear imaging represents the only imaging modality with sufficient sensitivity to assess myocardial
 blood flow and sympathetic innervation of the failing heart. Although nuclear imaging with single-photon emission computed
 tomography (SPECT) is most commonly used for the evaluation of myocardial perfusion, positron emission tomography (PET) allows
 absolute quantification of myocardial blood flow beyond the assessment of relative myocardial perfusion. Both techniques can
 be used for evalu...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4068268</comments>
            <pubDate>Mon, 11 Oct 2010 16:49:03 +0100</pubDate>
            <guid isPermaLink="false">4068268</guid>        </item>
        <item>
            <title>Pharmacologic modulation of parasympathetic activity in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=4046374&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgt23212456267133%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In the congestive heart failure state, autonomic dysregulation involves an increase in sympathetic tone and decrease in parasympathetic
 tone and is associated with increased mortality. It is possible that augmentation of the parasympathetic nervous system (PNS)
 with pharmacologic therapy may lead to improved symptoms and/or clinical outcomes. There are several new and established pharmacologic
 interventions that have been studied for their effect on the PNS, including antagonists of the renin–angiotensin system, beta-adrenergic
 antagonists, digoxin, and vasodilators. In this review, we discuss the current status of the published literature on pharmacologic
 influences on the PNS by both conventional and experimental drugs targeting heart failure as well as drugs t...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4046374</comments>
            <pubDate>Tue, 05 Oct 2010 18:07:07 +0100</pubDate>
            <guid isPermaLink="false">4046374</guid>        </item>
        <item>
            <title>Myocardial remodeling, an overview</title>
            <link>http://www.medworm.com/index.php?rid=4004978&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6786197mx306h34q%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s10741-010-9192-4Authors
		Dennis V. Cokkinos, Biomedical Research Foundation, Academy of Athens, Onassis Cardiac Surgery Center, 356 Sygrou Ave, Kallithea, 17674 Athens, GreeceCostas Pantos, Department of Pharmacology, University of Athens, 75 Mikras Asias Ave, Goudi, 11527 Athens, Greece
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4004978</comments>
            <pubDate>Sat, 25 Sep 2010 17:00:24 +0100</pubDate>
            <guid isPermaLink="false">4004978</guid>        </item>
        <item>
            <title>The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome</title>
            <link>http://www.medworm.com/index.php?rid=3999547&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg5l63516lr651620%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Anemia is common in Congestive Heart Failure (CHF) and is associated with an increased mortality, morbidity and progressive
 renal failure. The most common causes of the anemia in CHF are (1) the associated Chronic Kidney Disease (CKD), which causes
 depression of erythropoietin (EPO) production in the kidney, and (2) excessive cytokine production in CHF, which can cause
 both depression of erythropoietin production in the kidney and depression of erythropoietin response in the bone marrow. The
 cytokines can also induce iron deficiency by increasing hepcidin production from the liver, which both reduces gastrointestinal
 iron absorption and reduces iron release from iron stores located in the macrophages and hepatocytes. It appears that iron
 deficiency is very common ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3999547</comments>
            <pubDate>Thu, 23 Sep 2010 16:58:46 +0100</pubDate>
            <guid isPermaLink="false">3999547</guid>        </item>
        <item>
            <title>Significance of hyponatremia in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3978037&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl35617555l3347l1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure is one of the most common, costly, disabling and growing diseases (McMurray and Pfeffer in Lancet 365(9474):1877–1889,
 2005). Hyponatremia, conventionally defined as a serum-sodium concentration equal or less than 135&amp;nbsp;mmol/l (American Heart
 Association in Heart disease and stroke statistics—2007 update. American Heart Association, Dallas, 2007; Stewart et al. in
 Eur J Heart Fail 4:361–371, 2002), is a common phenomenon in patients with heart failure, with an incidence of 20–25% (Krumholz
 et al. in Arch Intern Med 157:e99–e104, 1997; Rosamond et al. in Circulation 117(4):e25–e146, 2008; Adrogue and Madias in
 N Engl J Med 342:1581–1589, 2000) and seems to be of prognostic importance in patients with heart failure (Luca et al. in
 Am J...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3978037</comments>
            <pubDate>Mon, 13 Sep 2010 17:05:25 +0100</pubDate>
            <guid isPermaLink="false">3978037</guid>        </item>
        <item>
            <title>Evidence for impaired vagus nerve activity in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3947848&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw511mv827q53m243%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Parasympathetic control of the heart via the vagus nerve is the primary mechanism that regulates beat-to-beat control of heart
 rate. Additionally, the vagus nerve exerts significant effects at the AV node, as well as effects on both atrial and ventricular
 myocardium. Vagal control is abnormal in heart failure, occurring at early stages of left ventricular dysfunction, and this
 reduced vagal function is associated with worse outcomes in patients following myocardial infarction and with heart failure.
 While central control mechanisms are abnormal, one of the primary sites of attenuated vagal control is at the level of the
 parasympathetic ganglion. It remains to be seen whether or not preventing or treating abnormal vagal control of the heart
 improves prognosis.
 
 
...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3947848</comments>
            <pubDate>Tue, 07 Sep 2010 07:07:49 +0100</pubDate>
            <guid isPermaLink="false">3947848</guid>        </item>
        <item>
            <title>Emerging therapies for heart failure: renal mechanisms and effects</title>
            <link>http://www.medworm.com/index.php?rid=3916585&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F85h63362370313l6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Improved understanding of the pathophysiology of salt and water homeostasis has provided a foundation for explaining the renal
 mechanisms of emerging therapies for heart failure, as well as why renal function might potentially be improved or harmed.
 These aspects are reviewed in this article for a number of newer therapies including adenosine, endothelin, and vasopressin
 receptor antagonists, as well as extracorporeal ultrafiltration. An appreciation of the complexity and sometimes opposing
 pathways of these approaches may explain their limited efficacy in early trials, in which there has not been a substantial
 improvement in patient or renal outcomes. In that there is often a balance between beneficial and maladaptive receptor actions
 and neurohumoral responses, ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3916585</comments>
            <pubDate>Mon, 30 Aug 2010 05:59:04 +0100</pubDate>
            <guid isPermaLink="false">3916585</guid>        </item>
        <item>
            <title>Innate immunity and remodelling</title>
            <link>http://www.medworm.com/index.php?rid=3865952&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg345v657417207q7%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A wide variety of cardiac disease states can induce remodelling and lead to the functional consequence of heart failure. These
 complex disease states involve a plethora of parallel signal transduction events, which may be associated with tissue injury
 or tissue repair. Innate immunity is activated in hearts injured in different ways, evident as cytokine release from the heart,
 activation of toll-like receptors involved in recognizing danger, and activation of the transcription factor nuclear factor
 kappa B. Nuclear factor kappa B regulates gene programmes involved in inflammation as well as the resolution of inflammation.
 The impact of this is an enigma; while cytokines, toll-like receptors, and nuclear factor kappa B appear to elicit myocardial
 protection in stud...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3865952</comments>
            <pubDate>Mon, 09 Aug 2010 05:44:37 +0100</pubDate>
            <guid isPermaLink="false">3865952</guid>        </item>
        <item>
            <title>Editorial</title>
            <link>http://www.medworm.com/index.php?rid=3828904&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F232716135737t543%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s10741-010-9189-zAuthors
		Bodh I. Jugdutt, University of Alberta Division of Cardiology, Department of Medicine and Cardiovascular Research Group, Faculty of Medicine, 2C2 Walter MacKenzie Health Sciences Centre Edmonton AB T6G 2R7 Canada
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3828904</comments>
            <pubDate>Wed, 04 Aug 2010 20:50:03 +0100</pubDate>
            <guid isPermaLink="false">3828904</guid>        </item>
        <item>
            <title>Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?</title>
            <link>http://www.medworm.com/index.php?rid=3818093&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F09843167676h2276%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic cytokine usually used in the treatment of patients with cancer.
 Studies have shown regenerative properties of bone marrow stem cell mobilization due to G-CSF in animals. Moreover, others
 effects related to G-CSF and independent of tissue regeneration were shown to be protective. As a result, this cytokine has
 been tested as a therapy for ischemic heart failure in humans. However, when this treatment was evaluated in clinical trials,
 the beneficial effects seen in small animals were not confirmed in infarcted patients. Thus, we sought to review the effects
 of G-CSF after an ischemic insult and on the progression of heart failure in animals and humans.
 
 
	Content Type Journal ArticleDOI 10.1007/s10741...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3818093</comments>
            <pubDate>Mon, 02 Aug 2010 20:11:57 +0100</pubDate>
            <guid isPermaLink="false">3818093</guid>        </item>
        <item>
            <title>New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider?</title>
            <link>http://www.medworm.com/index.php?rid=3808128&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F15761616l2804223%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic ischemia or pressure overload decreases thyroid hormone (TH) signaling and activates the fetal gene program in the
 heart. While these features are of physiologic importance in the developing heart, their respective roles in the postnatal
 heart are debated. Administration of TH can prevent the changes of the fetal gene program and rebuild the heart after an “index
 event” such as ischemia. TH affects cardiac remodeling by limiting reperfusion injury, and, at later states, by inducing distinct
 changes in cardiac chamber geometry in a time-dependent manner. Furthermore, administration of TH can convert pathologic to
 physiologic hypertrophy. These effects are the result of favorable cellular remodeling. While preliminary clinical studies
 provide encouraging...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3808128</comments>
            <pubDate>Thu, 29 Jul 2010 16:07:10 +0100</pubDate>
            <guid isPermaLink="false">3808128</guid>        </item>
        <item>
            <title>Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation</title>
            <link>http://www.medworm.com/index.php?rid=3791852&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe579462512534t13%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In heart failure, an inflammatory response may occur. The relationship between inflammatory cytokines, NOS and heart failure
 progression remains uncertain. Parasympathetic activation can affect heart rate and AV conduction. In heart failure, a relationship
 between the vagus nerve and the inflammatory response has been proposed. Vagal nerve stimulation can modulate the inflammatory
 response and affect specific inflammatory mediators including nitric oxide that may be contributory to continued or progressive
 heart failure. Therefore, vagal nerve stimulation may have beneficial effects that are independent from heart rate or AV conduction
 in heart failure. Challenges remain regarding the relationship between specific inflammatory markers and heart failure and
 how to ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3791852</comments>
            <pubDate>Sat, 24 Jul 2010 20:05:58 +0100</pubDate>
            <guid isPermaLink="false">3791852</guid>        </item>
        <item>
            <title>NADPH oxidases and cardiac remodelling</title>
            <link>http://www.medworm.com/index.php?rid=3791851&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn3t730g7380868x8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A heart under chronic stress undergoes cardiac remodelling, a process that comprises structural and functional changes including
 cardiomyocyte hypertrophy, interstitial fibrosis, contractile dysfunction, cell death and ventricular dilatation. Reactive
 oxygen species (ROS)-dependent modulation of intracellular signalling is implicated in the development of cardiac remodelling.
 Among the different ROS sources that are present in the heart, NADPH oxidases (NOXs) are particularly important in redox signalling.
 NOX isoforms are expressed in multiple cell types including cardiomyocytes, fibroblasts, endothelial cells and inflammatory
 cells—with the two main isoforms expressed in the heart being NOX2 and NOX4. Recent studies indicate that NOX-dependent signalling
 is in...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3791851</comments>
            <pubDate>Sat, 24 Jul 2010 20:05:58 +0100</pubDate>
            <guid isPermaLink="false">3791851</guid>        </item>
        <item>
            <title>Modulation of β-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5</title>
            <link>http://www.medworm.com/index.php?rid=3791853&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjj7474270132p808%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Despite remarkable advances in therapy, heart failure remains a leading cause of morbidity and mortality. Although enhanced
 β-adrenergic receptor stimulation is part of normal physiologic adaptation to either the increase in physiologic demand or
 decrease in cardiac function, chronic β-adrenergic stimulation has been associated with increased mortality and morbidity
 in both animal models and humans. For example, overexpression of cardiac Gsα or β-adrenergic receptors in transgenic mice
 results in enhanced cardiac function in young animals, but with prolonged overstimulation of this pathway, cardiomyopathy
 develops in these mice as they age. Similarly, chronic sympathomimetic amine therapy increases morbidity and mortality in
 patients with heart failure. Conver...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3791853</comments>
            <pubDate>Sat, 24 Jul 2010 13:49:01 +0100</pubDate>
            <guid isPermaLink="false">3791853</guid>        </item>
        <item>
            <title>Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities</title>
            <link>http://www.medworm.com/index.php?rid=3747810&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4k440mt3h7381867%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;As more patients survive myocardial infarctions, the incidence of heart failure increases. After an infarction, the human
 heart undergoes a series of structural changes, which are governed by cellular and molecular mechanisms in a pathological
 metamorphosis termed “remodeling.” This review will discuss the current developments in our understanding of these molecular
 and cellular events in remodeling and the various pharmacological, cellular and device therapies used to treat, and potentially
 retard, this condition. Specifically, this paper will examine the neurohormonal activity of the renin–angiotensin–aldosterone
 axis and its molecular effects on the heart. The emerging understanding of the extra-cellular matrix and the various active
 molecules within it...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3747810</comments>
            <pubDate>Sat, 10 Jul 2010 06:46:37 +0100</pubDate>
            <guid isPermaLink="false">3747810</guid>        </item>
        <item>
            <title>Histopathology of the stimulated Vagus nerve: primum non nocere</title>
            <link>http://www.medworm.com/index.php?rid=3747811&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk2n4452453t71h77%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A primary concern in the utilization of implantable neural interfaces for the treatment of medical diseases is to follow the
 Hippocratic dictum: First, do no harm. If we are to avoid harm to the Vagus nerve in our use of stimulatory electrodes in the treatment of heart failure, we must
 understand the structural and functional elements that comprise peripheral nerves, their susceptibility to various types of
 injury that might be expected to occur secondary to functional electrical stimulation and how to separate the various components
 of the response of peripheral nervous system elements to stresses that may occur in the complex interactions that take place
 between electrode and nerve. To this end, we review the functional histology of peripheral nerve, followed by ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3747811</comments>
            <pubDate>Sat, 10 Jul 2010 06:46:36 +0100</pubDate>
            <guid isPermaLink="false">3747811</guid>        </item>
        <item>
            <title>Methods of assessing vagus nerve activity and reflexes</title>
            <link>http://www.medworm.com/index.php?rid=3700428&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F429w4j1647n21v3g%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The methods used to assess cardiac parasympathetic (cardiovagal) activity and its effects on the heart in both humans and
 animal models are reviewed. Heart rate (HR)-based methods include measurements of the HR response to blockade of muscarinic
 cholinergic receptors (parasympathetic tone), beat-to-beat HR variability (HRV) (parasympathetic modulation), rate of post-exercise
 HR recovery (parasympathetic reactivation), and reflex-mediated changes in HR evoked by activation or inhibition of sensory
 (afferent) nerves. Sources of excitatory afferent input that increase cardiovagal activity and decrease HR include baroreceptors,
 chemoreceptors, trigeminal receptors, and subsets of cardiopulmonary receptors with vagal afferents. Sources of inhibitory
 afferent input incl...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3700428</comments>
            <pubDate>Fri, 25 Jun 2010 16:55:30 +0100</pubDate>
            <guid isPermaLink="false">3700428</guid>        </item>
        <item>
            <title>Sympathetic–parasympathetic interaction in health and disease: abnormalities and relevance in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3700427&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc971023t01238858%2F</link>
            <description>This article reviews the background of sympathetic–parasympathetic interactions focusing
 on the best direct evidence available, namely direct neural recordings of the activity of single vagal and sympathetic fibers
 directed to the heart. It examines indirect but highly reliable markers of this interaction as they can be studied in the
 clinical setting of ischemic heart disease and of heart failure, focusing primarily on the experimental and clinical studies
 of baroreflex sensitivity. It concludes by drawing inferences likely to lead to a novel approach to the management of heart
 failure, resulting from the knowledge gained about the vagal control of the heart and based on electrical vagal stimulation.
 
 
	Content Type Journal ArticleDOI 10.1007/s10741-010-9179-1Authors
		Peter J. S...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3700427</comments>
            <pubDate>Fri, 25 Jun 2010 16:55:30 +0100</pubDate>
            <guid isPermaLink="false">3700427</guid>        </item>
        <item>
            <title>Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms</title>
            <link>http://www.medworm.com/index.php?rid=3692381&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9g603216p7103345%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac dysfunction is a well-recognized complication of severe sepsis and septic shock. Cardiac dysfunction in sepsis is
 characterized by ventricular dilatation, reduction in ejection fraction and reduced contractility. Initially, cardiac dysfunction
 was considered to occur only during the “hypodynamic” phase of shock. But we now know that it occurs very early in sepsis
 even during the “hyperdynamic” phase of septic shock. Circulating blood-borne factors were suspected to be involved in the
 evolution of sepsis induced cardiomyopathy, but it is not until recently that the cellular and molecular events are being
 targeted by researchers in a quest to understand this enigmatic process. Septic cardiomyopathy has been the subject of investigation
 for nearly hal...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3692381</comments>
            <pubDate>Wed, 23 Jun 2010 08:22:32 +0100</pubDate>
            <guid isPermaLink="false">3692381</guid>        </item>
        <item>
            <title>TNFα in myocardial ischemia/reperfusion, remodeling and heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3692382&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg52tghr817788g52%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;TNFα is crucially involved in the pathogenesis and progression of myocardial ischemia/reperfusion injury and heart failure.
 The formation and release of TNFα and its downstream signal transduction cascade following activation of its two receptor
 subtypes are characterized. Myocardial TNFα and TNF receptor activation have an ambivalent role in myocardial ischemia/reperfusion
 injury and protection from it. Excessive TNFα expression and subsequent cardiomyocyte TNF receptor type 1 stimulation induce
 contractile dysfunction, hypertrophy, fibrosis and cell death, while a lower TNFα concentration and subsequent cardiomyocyte
 TNF receptor type 2 stimulation are protective. Apart from its concentration and receptor subtype, the myocardial action of
 TNFα depends on t...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3692382</comments>
            <pubDate>Wed, 23 Jun 2010 08:22:30 +0100</pubDate>
            <guid isPermaLink="false">3692382</guid>        </item>
        <item>
            <title>Arrhythmias and vagus nerve stimulation</title>
            <link>http://www.medworm.com/index.php?rid=3677802&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9225x28707728384%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Enhancing vagal tone by delivering electrical stimulation to the vagal nerves (VNS) is emerging as a promising novel therapy
 in heart failure. In addition, VNS is already an FDA-approved therapy for refractory epilepsy and depression. Besides its
 well-known negative chronotropic, inotropic, and dromotropic effects, VNS has profound effects on cardiac electrophysiology
 and arrhythmogenesis. This review summarizes current knowledge about the complex relationship between VNS and cardiac arrhythmias.
 Specifically, the focus is on VNS capability to become a therapeutic strategy along with important electrophysiological alterations
 that may constitute a potential arrhythmogenic substrate and become a clinical concern.
 
 
	Content Type Journal ArticleDOI 10.1007/s10741-0...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3677802</comments>
            <pubDate>Fri, 18 Jun 2010 10:37:28 +0100</pubDate>
            <guid isPermaLink="false">3677802</guid>        </item>
        <item>
            <title>Stem cells in the diabetic infarcted heart</title>
            <link>http://www.medworm.com/index.php?rid=3677803&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq1410t84t775k261%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Diabetes mellitus is one of the leading causes of death, and the majority of these deaths are associated with cardiovascular
 diseases. Development and progression of myocardial infarction leading to heart failure is much more complex and multifactorial in
 diabetics compared with non-diabetics. Despite significant advances in pharmacological interventions and surgical techniques,
 the disease progression leading to diabetic end-stage heart failure remains very high. Recently, cell therapy has gained much
 attention as an alternative approach to treat various heart diseases. However, transplanted stem cell studies in diabetic
 animal models are very limited. In this review, we discuss the pathogenesis of the diabetic infarcted heart and the potential
 of stem cell thera...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3677803</comments>
            <pubDate>Fri, 18 Jun 2010 10:37:27 +0100</pubDate>
            <guid isPermaLink="false">3677803</guid>        </item>
        <item>
            <title>Left ventricular non-compaction and its cardiac and neurologic implications</title>
            <link>http://www.medworm.com/index.php?rid=3667739&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb218mu2883x29320%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Left ventricular non-compaction, also known as left ventricular hypertrabeculation (LVHT), is a morphological abnormality
 of the left ventricular myocardium, characterised by a meshwork of myocardial strings, interlacing, and orderless in arrangement.
 LVHT is most frequently located in the apex and the lateral wall and may occur with or without other congenital or acquired
 cardiac abnormalities. LVHT is believed to be congenital in the majority of the cases but may develop during life in single
 cases (acquired LVHT). Congenital LVHT is believed to result from defective late-stage embryonic development of the myocardial
 architecture. The pathogenesis of acquired LVHT remains speculative. LVHT is most frequently found on transthoracic echocardiography
 and cardiac MR...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3667739</comments>
            <pubDate>Mon, 14 Jun 2010 14:08:47 +0100</pubDate>
            <guid isPermaLink="false">3667739</guid>        </item>
        <item>
            <title>STEMI and heart failure in the elderly: role of adverse remodeling</title>
            <link>http://www.medworm.com/index.php?rid=3667738&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk86tp82q60w1t432%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The elderly population (age ≥&amp;nbsp;65 years) has been increasing worldwide. In North America and Europe, both heart failure (HF)
 and ST-segment elevation MI (STEMI) are more prevalent in the elderly. Morbidity, hospitalizations and costs associated with
 HF are higher in the elderly. Despite improved therapies, the bulk of cardiovascular deaths occur in the elderly. Survivors
 of acute STEMI develop progressive ventricular remodeling that leads to HF. There are several reasons for the increased HF
 burden in the elderly. First, there is a lack of clinical trial data exclusively in elderly patients for specific therapy
 of adverse remodeling post-STEMI and HF with low ejection fraction (HF/low-EF) or HF with preserved ejection fraction (HF/PEF).
 Second, there is the ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3667738</comments>
            <pubDate>Mon, 14 Jun 2010 14:08:47 +0100</pubDate>
            <guid isPermaLink="false">3667738</guid>        </item>
        <item>
            <title>Aging, telomeres and heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3653540&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm54435608500120w%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;During normal aging, the heart undergoes functional, morphological and cellular changes. Although aging per se does not lead
 to the expression of heart failure, it is likely that age-associated changes lower the threshold for the manifestation of
 signs and symptoms of heart failure. In patients, the susceptibility, age of onset and pace of progression of heart failure
 are highly variable. The presence of conventional risk factors cannot completely explain this variability. Accumulation of
 DNA damage and telomere attrition results in an increase in cellular senescence and apoptosis, resulting in a decrease in
 the number and function of cells, contributing to the overall tissue and organ dysfunction. Biological aging, characterized
 by reduced telomere length, provid...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3653540</comments>
            <pubDate>Wed, 09 Jun 2010 09:25:53 +0100</pubDate>
            <guid isPermaLink="false">3653540</guid>        </item>
        <item>
            <title>Functional electrical stimulation of lower limbs in patients with chronic heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3587051&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr12lm04q6360m567%2F</link>
            <description>We present a review of the numerous
 studies evaluating the effects of FES in CHF, focusing on its main effects on skeletal myopathy reversal, exercise tolerance
 improvement and quality of life modification.
 
 
	Content Type Journal ArticleDOI 10.1007/s10741-010-9171-9Authors
		Apostolos Karavidas, G. Gennimatas’ General Hospital of Athens Mesogion 156 Athens GreeceSophia M. Arapi, G. Gennimatas’ General Hospital of Athens Mesogion 156 Athens GreeceVlassios Pyrgakis, G. Gennimatas’ General Hospital of Athens Mesogion 156 Athens GreeceStamatis Adamopoulos, Onassis Cardiac Surgery Center Second Cardiology Department Athens Greece
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3587051</comments>
            <pubDate>Thu, 20 May 2010 16:57:54 +0100</pubDate>
            <guid isPermaLink="false">3587051</guid>        </item>
        <item>
            <title>Modulation of sarcoplasmic reticulum Ca2+ cycling in systolic and diastolic heart failure associated with aging</title>
            <link>http://www.medworm.com/index.php?rid=3509075&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F38797801qh301263%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hypertension, atherosclerosis, and resultant chronic heart failure (HF) reach epidemic proportions among older persons, and
 the clinical manifestations and the prognoses of these worsen with increasing age. Thus, age per se is the major risk factor
 for cardiovascular disease. Changes in cardiac cell phenotype that occur with normal aging, as well as in HF associated with
 aging, include deficits in ß-adrenergic receptor (ß-AR) signaling, increased generation of reactive oxygen species (ROS),
 and altered excitation–contraction (EC) coupling that involves prolongation of the action potential (AP), intracellular Ca2+ (Cai2+) transient and contraction, and blunted force- and relaxation-frequency responses. Evidence suggests that altered sarcoplasmic
 reticulum (SR) C...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3509075</comments>
            <pubDate>Sat, 24 Apr 2010 08:08:16 +0100</pubDate>
            <guid isPermaLink="false">3509075</guid>        </item>
        <item>
            <title>STAT3 and cardiac remodeling</title>
            <link>http://www.medworm.com/index.php?rid=3495248&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhp370tqt3j75246g%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Multiple in vitro and in vivo studies showed that the signal transducer and activator of transcription 3 (STAT3) protein is
 involved in cardiomyocyte protection and hypertrophy and via paracrine pathways impacts on the non-myocyte compartment, i.e.,
 the vasculature and the extracellular matrix. In this regard, STAT3 interacts with a broad range of cellular and molecular
 mechanisms that direct remodeling processes in cardiac physiology (exercise, pregnancy) and pathophysiology (pressure overload,
 ischemia/reperfusion, myocardial infarction, and cardiotoxic agents). STAT3 is constitutively activated by a multitude of
 factors including cytokines, growth factors, neurohormones, mechanical load, and ischemia. It acts as a signaling molecule,
 a transcription factor and ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3495248</comments>
            <pubDate>Wed, 21 Apr 2010 09:20:34 +0100</pubDate>
            <guid isPermaLink="false">3495248</guid>        </item>
        <item>
            <title>Cellular and molecular pathways to myocardial necrosis and replacement fibrosis</title>
            <link>http://www.medworm.com/index.php?rid=3491661&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh0p53471mj572713%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Fibrosis is a fundamental component of the adverse structural remodeling of myocardium present in the failing heart. Replacement
 fibrosis appears at sites of previous cardiomyocyte necrosis to preserve the structural integrity of the myocardium, but not
 without adverse functional consequences. The extensive nature of this microscopic scarring suggests cardiomyocyte necrosis
 is widespread and the loss of these contractile elements, combined with fibrous tissue deposition in the form of a stiff in-series
 and in-parallel elastic elements, contributes to the progressive failure of this normally efficient muscular pump. Cellular
 and molecular studies into the signal-transducer-effector pathway involved in cardiomyocyte necrosis have identified the crucial
 pathogenic ro...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3491661</comments>
            <pubDate>Tue, 20 Apr 2010 11:06:15 +0100</pubDate>
            <guid isPermaLink="false">3491661</guid>        </item>
        <item>
            <title>Proinflammatory cytokines in heart failure: double-edged swords</title>
            <link>http://www.medworm.com/index.php?rid=3491662&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq2m08932173k7t31%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Increased circulating and intracardiac levels of proinflammatory cytokines have been associated with chronic heart failure.
 Following an initial insult, the increased production of proinflammatory cytokines, including TNF-α, IL-6, IL-1, and IL-18,
 jeopardizes the surrounding tissue through propagation of the inflammatory response and direct effects on the cardiac myocyte
 structure and function. Cardiac myocyte hypertrophy, contractile dysfunction, cardiac myocyte apoptosis, and extracellular
 matrix remodeling contribute enormously to the development and progression of chronic heart failure. Despite the identification
 of efficacious pharmacological regimens and introduction of mechanical interventions, chronic heart failure remains among
 the leading causes of mort...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3491662</comments>
            <pubDate>Tue, 20 Apr 2010 11:06:14 +0100</pubDate>
            <guid isPermaLink="false">3491662</guid>        </item>
        <item>
            <title>Role of autophagy in heart failure associated with aging</title>
            <link>http://www.medworm.com/index.php?rid=3469163&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx1r7554753u63v90%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure is a progressive disease, leading to reduced quality of life and premature death. Adverse ventricular remodeling
 involves changes in the balance between cardiomyocyte protein synthesis and degradation, forcing these myocytes in equilibrium
 between life and death. In this context, autophagy has been recognized to play a role in the pathophysiology of heart failure.
 At basal levels, autophagy performs housekeeping functions, maintaining cardiomyocyte function and ventricular mass. Autophagy
 also occurs in the failing human heart, and upregulation has been reported in animal models of pressure overload–induced heart
 failure. Although the factors that determine whether autophagy will be protective or detrimental are not well known, the level
 and durati...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3469163</comments>
            <pubDate>Sat, 10 Apr 2010 07:49:22 +0100</pubDate>
            <guid isPermaLink="false">3469163</guid>        </item>
        <item>
            <title>Control of autocrine and paracrine myocardial signals: an emerging therapeutic strategy in heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3445010&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Frm3u7u86r16104l2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A growing body of evidence supports the hypothesis that autocrine and paracrine mechanisms, mediated by factors released by
 the resident cardiac cells, could play an essential role in the reparative process of the failing heart. Such signals may
 influence the function of cardiac stem cells via several mechanisms, among which the most extensively studied are cardiomyocyte
 survival and angiogenesis. Moreover, besides promoting cytoprotection and angiogenesis, paracrine factors released by resident
 cardiac cells may alter cardiac metabolism and extracellular matrix turnover, resulting in more favorable post-injury remodeling.
 It is reasonable to believe that critical intracellular signals are activated and modulated in a temporal and spatial manner
 exerting different...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3445010</comments>
            <pubDate>Sat, 03 Apr 2010 07:16:15 +0100</pubDate>
            <guid isPermaLink="false">3445010</guid>        </item>
        <item>
            <title>Aging and heart failure: changing demographics and implications for therapy in the elderly</title>
            <link>http://www.medworm.com/index.php?rid=3445011&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9510024655vj167x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The elderly population (age ≥65) is increasing and with it morbidity, hospitalizations, costs and mortality due to heart failure
 (HF). HF is a progressive disorder that is superimposed on an on-going aging process. The two broad categories of HF, HF with
 left ventricular (LV) systolic dysfunction or low ejection fraction (HF/low-EF) and HF with preserved ejection fraction (HF/PEF)
 are equally prevalent in the elderly. Trials of therapy for HF/low-EF in primarily non-elderly patients showed mortality benefit
 in elderly patients. In contrast, trials for HF/PEF have not shown mortality benefit in elderly or non-elderly patients. HF
 pharmacotherapy in the elderly is challenging and needs to be individualized and consider several aging-related changes. More
 research ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3445011</comments>
            <pubDate>Sat, 03 Apr 2010 07:16:14 +0100</pubDate>
            <guid isPermaLink="false">3445011</guid>        </item>
        <item>
            <title>Resveratrol and red wine, healthy heart and longevity</title>
            <link>http://www.medworm.com/index.php?rid=3386332&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F86r10731k8806133%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Resveratrol, a polyphenol phytoalexin, present in red wine and grapes possesses diverse biochemical and physiological properties,
 including estrogenic, antiplatelet, and anti-inflammatory properties as well as a wide range of health benefits ranging from
 chemoprevention to cardioprotection. Recently, several studies described resveratrol as an anti-aging compound. This review
 focuses on the anti-aging aspects of resveratrol, the possible mechanisms of action, and emerging controversy on its life-prolonging
 ability. It appears that resveratrol can induce the expression of several longevity genes including Sirt1, Sirt3, Sirt4, FoxO1, Foxo3a and PBEF and prevent aging-related decline in cardiovascular function including cholesterol level and inflammatory response, but ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386332</comments>
            <pubDate>Thu, 18 Mar 2010 15:36:57 +0100</pubDate>
            <guid isPermaLink="false">3386332</guid>        </item>
        <item>
            <title>Stem cells for heart failure in the aging heart</title>
            <link>http://www.medworm.com/index.php?rid=3360418&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Faj08552540511724%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Despite a wide range of therapeutic interventions, the prognosis for most patients with heart failure remains poor. The identification
 of stem cells with the ability to generate cardiomyocytes and vascular cells and promote local repair and survival pathways
 has highlighted the ability of the heart to undergo regeneration and potentially provides a new therapeutic strategy for treatment
 of the failing heart. In recent years, however, clinical trials aimed at exploiting the beneficial effects of stem and progenitor
 cells to treat patients with cardiovascular disease have resulted in mild improvements at best, suggesting that these cells
 and/or the conditions in which they find themselves are not conducive to cardiac repair. Heart failure is most prevalent among
 old...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360418</comments>
            <pubDate>Thu, 11 Mar 2010 18:24:42 +0100</pubDate>
            <guid isPermaLink="false">3360418</guid>        </item>
        <item>
            <title>The role of inflammatory and fibrogenic pathways in heart failure associated with aging</title>
            <link>http://www.medworm.com/index.php?rid=3355765&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd342417k43702884%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart failure is strongly associated with aging. Elderly patients with heart failure often have preserved systolic function
 exhibiting left ventricular hypertrophy accompanied by a decline in diastolic function. Experimental studies have demonstrated
 that age-related cardiac fibrosis plays an important role in the pathogenesis of diastolic heart failure in senescent hearts.
 Reactive oxygen species and angiotensin II are critically involved in fibrotic remodeling of the aging ventricle; their fibrogenic
 actions may be mediated, at least in part, through transforming growth factor (TGF)-β. The increased prevalence of heart failure
 in the elderly is also due to impaired responses of the senescent heart to cardiac injury. Aging is associated with suppressed
 inflammat...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355765</comments>
            <pubDate>Wed, 10 Mar 2010 16:17:30 +0100</pubDate>
            <guid isPermaLink="false">3355765</guid>        </item>
        <item>
            <title>The epidemiology and management of elderly patients with myocardial infarction or heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3355764&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw00ggp55g72t1t31%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Heart disease is important in elderly patients. The treatment of myocardial infarction and heart failure are particularly
 important and will continue to play an important role across the globe. Advances in treatment of myocardial infarction have
 made tremendous inroads in the short and long term survival of patients, young and old, however, many currently employed strategies
 have not been tested in patients who are elderly, who paradoxically, form a growing subset of patients with heart disease.
 A similar paradigm exists in heart failure for both diagnosis and treatment. Attention to this issue is important when selecting
 treatment strategies and a focus on the goals of care is critical when decisions for care must be undertaken.
 
 
	Content Type Journal ArticleDO...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355764</comments>
            <pubDate>Wed, 10 Mar 2010 16:17:30 +0100</pubDate>
            <guid isPermaLink="false">3355764</guid>        </item>
        <item>
            <title>Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease</title>
            <link>http://www.medworm.com/index.php?rid=3355766&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F54028752274l4178%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Adiponectin is an adipose tissue-derived adipokine abundant in human plasma. Increasing evidence from experimental studies
 suggests that adiponectin plays a protective role in the cardiovascular system. However, epidemiological studies revealed
 that high levels of adiponectin were associated with increased mortality and severity of congestive heart failure. Furthermore,
 several prospective studies indicated that high levels of adiponectin were positively correlated with increased total and
 cardiovascular disease mortality in the elderly. These results are completely opposite to our expectation based on the beneficial
 effects of adiponectin. Clinical observations demonstrated that plasma adiponectin levels were positively associated with
 B-type natriuretic peptide ...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355766</comments>
            <pubDate>Wed, 10 Mar 2010 16:17:29 +0100</pubDate>
            <guid isPermaLink="false">3355766</guid>        </item>
        <item>
            <title>Role of osteopontin in heart failure associated with aging</title>
            <link>http://www.medworm.com/index.php?rid=3240976&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp3242g608g035011%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiovascular disease is one of the leading causes of death in the elderly. Much of the morbidity and mortality in the elderly
 is attributable to acute ischemic events leading to myocardial infarction (MI) and death of cardiac myocytes. Evidence has
 been provided that aging associated with adverse remodeling post MI as demonstrated by less effective myocardial repair, greater
 infarct expansion, and septal hypertrophy. Expression of osteopontin (OPN) increases in the heart post MI. Transgenic mice
 studies suggest that increased expression of OPN plays a protective role in post-MI LV remodeling by modulating collagen deposition
 and fibrosis. OPN, a multifunctional protein, has the potential to influence the molecular and cellular changes associated
 with infarct hea...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3240976</comments>
            <pubDate>Tue, 02 Feb 2010 17:51:25 +0100</pubDate>
            <guid isPermaLink="false">3240976</guid>        </item>
        <item>
            <title>Role and benefits of exercise in the management of patients with heart failure</title>
            <link>http://www.medworm.com/index.php?rid=3209632&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb47188u823816454%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Initial research established the feasibility of exercise training in patients with heart failure, as well as associated physiological
 benefits. This review summarizes the findings from over two dozen single-site studies that address the effect of exercise
 training on exercise capacity and cardiovascular and peripheral function. In addition, it incorporates the results from two
 meta-analyses and a recently completed multi-center trial, all of which studied the effects of exercise training on clinical
 outcomes. The major conclusions from these studies are that exercise training is safe; improves health status and exercise
 capacity; helps attenuate much of the abnormal pathophysiology that develops with heart failure; and yields a modest reduction
 in clinical events....</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3209632</comments>
            <pubDate>Mon, 25 Jan 2010 17:01:05 +0100</pubDate>
            <guid isPermaLink="false">3209632</guid>        </item>
        <item>
            <title>Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics</title>
            <link>http://www.medworm.com/index.php?rid=3040898&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F745v75961181px24%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by the absence of dystrophin, a sarcolemmal protein
 which links the cytoskeleton to the extracellular matrix by interacting with a large number of proteins. Heart failure is
 a classic complication of this disease. The authors review the pathogenesis and therapeutics of cardiac involvement in DMD.
 
	Content Type Journal ArticleDOI 10.1007/s10741-009-9156-8Authors
		Abdallah Fayssoil, University of Medicine and Dentistry of New Jersey Camden NJ USAOlivier Nardi, Raymond Poincaré Hospital, AP-HP Intensive Care Unit Garches FranceDavid Orlikowski, Raymond Poincaré Hospital, AP-HP Intensive Care Unit Garches FranceDjillali Annane, Raymond Poincaré Hospital, AP-HP Intensive Care Unit Garches Fran...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3040898</comments>
            <pubDate>Fri, 27 Nov 2009 07:06:28 +0100</pubDate>
            <guid isPermaLink="false">3040898</guid>        </item>
        <item>
            <title>George C. Sutton, Kanu Chatterjee: Heart failure: current clinical understanding</title>
            <link>http://www.medworm.com/index.php?rid=2996831&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe7850u66221u0v76%2F</link>
            <description>Content Type Journal ArticleCategory Book ReviewDOI 10.1007/s10741-009-9155-9Authors
		Sidney Goldstein, Wayne State University Detroit MI USA
	

	
		Journal Heart Failure ReviewsOnline ISSN 1573-7322Print ISSN 1382-4147 (Source: Heart Failure Reviews)</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2996831</comments>
            <pubDate>Fri, 13 Nov 2009 18:28:44 +0100</pubDate>
            <guid isPermaLink="false">2996831</guid>        </item>
        <item>
            <title>Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond</title>
            <link>http://www.medworm.com/index.php?rid=2947879&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0454480241703821%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Treatment with inotropic agents is one of the most controversial topics in heart failure. Initial enthusiasm, based on strong
 pathophysiological rationale and apparent empirical efficacy, has been progressively limited by results of controlled trials
 and registries showing poorer outcomes of the patients on inotropic therapy. The use of these agents remains, however, potentially
 indicated in a significant proportion of patients with low cardiac output, peripheral hypoperfusion and end-organ dysfunction
 caused by heart failure. Limitations of inotropic therapy seem to be mainly related to their mechanisms of action entailing
 arrhythmogenesis, peripheral vasodilation, myocardial ischemia and damage, and possibly due to their use in patients without
 a clear indicatio...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2947879</comments>
            <pubDate>Thu, 29 Oct 2009 19:51:20 +0100</pubDate>
            <guid isPermaLink="false">2947879</guid>        </item>
        <item>
            <title>Do we have two hearts? New insights in right ventricular function supported by myocardial imaging echocardiography</title>
            <link>http://www.medworm.com/index.php?rid=2944975&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa85845x1jr061265%2F</link>
            <description>This article focuses on some of the challenges related to the assessment of RV function
 in the setting of the RV’s unique anatomic, physiologic, conventional and newer echocardiographic aspects, and therapeutic
 implications. The majority of proposed methods of echocardiographic assessment of RV function are based on volumetric approximations
 of the RV. Such approaches have inherent limitations, first as volume-related measures such as EF are load dependent, second
 because of the complex geometry of the RV. The issue of RV geometry is usually overcome using geometry-independent parameters
 such as tricuspid annular excursion and the Tei index. The recent introduction of real-time three-dimensional echocardiography
 and myocardial imaging echocardiography (tissue Doppler imaging, 1D-st...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944975</comments>
            <pubDate>Thu, 29 Oct 2009 07:23:04 +0100</pubDate>
            <guid isPermaLink="false">2944975</guid>        </item>
        <item>
            <title>Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure</title>
            <link>http://www.medworm.com/index.php?rid=2810719&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc8520pn66v3213gu%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;It is now becoming clear that two major systems namely the sympathetic nervous system and the renin-angiotensin system are
 activated in response to ischemic injury; these result in the elevation of plasma catecholamines and angiotensin II during
 the development of myocardial infarction as well as congestive heart failure. Although plasma levels of several other hormones
 including aldosterone, endothelin, vasopressin, natriuretic peptides, growth factors and inflammatory cytokines are also increased
 in heart failure, their relationship with changes in catecholamine and/or angiotensin levels as well as their significance
 for the induction of congestive heart failure are poorly understood. In this article we have examined the evidence regarding
 the role of endothelin...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2810719</comments>
            <pubDate>Fri, 18 Sep 2009 06:15:39 +0100</pubDate>
            <guid isPermaLink="false">2810719</guid>        </item>
        <item>
            <title>Architecture of the left ventricle: insights for optimal surgical ventricular restoration</title>
            <link>http://www.medworm.com/index.php?rid=2810720&amp;cid=s_33396_7_f&amp;fid=33396&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq073162j71m68777%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The normal left ventricular shape has been defined as prolate ellipsoid. This shape is an adaptation to evolution. A knowledge
 of its unique macro and micro architecture forms the cornerstone in the understanding of its complex function. The left ventricle
 has a unique architecture with three different myofiber orientations, the longitudinal, circumferential and oblique fibers.
 The oblique orientation of fibers is essential for effective clockwise and anticlockwise torsional movements during systole
 and diastole, for optimal ventricular ejection and filling. The orientation and fiber angle decide the shape of the ventricle.
 An ellipsoid shape is vital for optimal function. Pathological disease states such as ischemic heart disease, valvular heart
 disease and cardi...</description>
            <author>Heart Failure Reviews</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2810720</comments>
            <pubDate>Wed, 16 Sep 2009 12:56:36 +0100</pubDate>
            <guid isPermaLink="false">2810720</guid>        </item>
    </channel>
</rss>

